

Washington University School of Medicine Digital Commons@Becker

Open Access Publications

2008

The AP-2 adaptor $\beta 2$ appendage scaffolds alternate cargo endocytosis

Peter A. Keyel

University of Pittsburgh School of Medicine

James R. Thieman

University of Pittsburgh School of Medicine

Robyn Roth

Washington University School of Medicine in St. Louis

Elif Erkan

University of Pittsburgh School of Medicine

Eric T. Everett

University of North Carolina at Chapel Hill

See next page for additional authors

Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs

 Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Keyel, Peter A.; Thieman, James R.; Roth, Robyn; Erkan, Elif; Everett, Eric T.; Watkins, Simon C.; Heuser, John E.; and Traub, Linton M., "The AP-2 adaptor $\beta 2$ appendage scaffolds alternate cargo endocytosis." *Molecular Biology of the Cell*. 19,12. 5309-5326. (2008). http://digitalcommons.wustl.edu/open_access_pubs/417

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

Authors

Peter A. Keyel, James R. Thieman, Robyn Roth, Elif Erkan, Eric T. Everett, Simon C. Watkins, John E. Heuser, and Linton M. Traub

The AP-2 Adaptor $\beta 2$ Appendage Scaffolds Alternate Cargo Endocytosis

Peter A. Keyel,^{*†‡} James R. Thieman,^{*†} Robyn Roth,[§] Elif Erkan,^{||} Eric T. Everett,[¶] Simon C. Watkins,^{*} John E. Heuser,[§] and Linton M. Traub^{*}

^{*}Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261; [§]Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110; ^{||}Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213; and [¶]Department of Pediatric Dentistry and The Carolina Center for Genome Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599

Submitted July 11, 2008; Revised September 19, 2008; Accepted September 30, 2008
Monitoring Editor: Sandra Lemmon

The independently folded appendages of the large α and $\beta 2$ subunits of the endocytic adaptor protein (AP)-2 complex coordinate proper assembly and operation of endocytic components during clathrin-mediated endocytosis. The $\beta 2$ subunit appendage contains a common binding site for β -arrestin or the autosomal recessive hypercholesterolemia (ARH) protein. To determine the importance of this interaction surface in living cells, we used small interfering RNA-based gene silencing. The effect of extinguishing $\beta 2$ subunit expression on the internalization of transferrin is considerably weaker than an AP-2 α subunit knockdown. We show the mild sorting defect is due to fortuitous substitution of the $\beta 2$ chain with the closely related endogenous $\beta 1$ subunit of the AP-1 adaptor complex. Simultaneous silencing of both $\beta 1$ and $\beta 2$ subunit transcripts recapitulates the strong α subunit RNA interference (RNAi) phenotype and results in loss of ARH from endocytic clathrin coats. An RNAi-insensitive $\beta 2$ -yellow fluorescent protein (YFP) expressed in the $\beta 1$ + $\beta 2$ -silenced background restores cellular AP-2 levels, robust transferrin internalization, and ARH colocalization with cell surface clathrin. The importance of the β appendage platform subdomain over clathrin for precise deposition of ARH at clathrin assembly zones is revealed by a $\beta 2$ -YFP with a disrupted ARH binding interface, which does not restore ARH colocalization with clathrin. We also show a β -arrestin 1 mutant, which engages coated structures in the absence of any G protein-coupled receptor stimulation, colocalizes with $\beta 2$ -YFP and clathrin even in the absence of an operational clathrin binding sequence. These findings argue against ARH and β -arrestin binding to a site upon the $\beta 2$ appendage platform that is later obstructed by polymerized clathrin. We conclude that ARH and β -arrestin depend on a privileged $\beta 2$ appendage site for proper cargo recruitment to clathrin bud sites.

INTRODUCTION

Clathrin-mediated endocytosis is a process through which many nutrient and signaling receptors, ion channels, and even pathogens, are internalized from the cell surface and delivered to endosomes. The process requires the fine coordination

of cargo selection, membrane invagination, and actin dynamics (Conner and Schmid, 2003; Robinson, 2004; Edeling *et al.*, 2006b; Kaksonen *et al.*, 2006). At the plasma membrane, these diverse processes are managed, in part, by the adaptor protein (AP)-2 heterotetramer. The brick-like AP-2 core is composed of a small $\sigma 2$ subunit, the cargo-selective $\mu 2$ subunit, along with the N-terminal trunks of two large chains, the α and $\beta 2$ subunits (Collins *et al.*, 2002; see Figure 4A). Projecting off both α and $\beta 2$ subunit trunks, via flexible hinges, are bilobal appendages that contain binding sites for clathrin and numerous other endocytic proteins (Robinson, 2004; Edeling *et al.*, 2006b; Schmid and McMahon, 2007).

The four assembled subunits permit AP-2 to coordinate various aspects of clathrin coat formation. The plasma membrane-enriched lipid phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P₂] is engaged by both the α and $\mu 2$ subunits (Gaidarov and Keen, 1999; Höning *et al.*, 2005). YXX ϕ -type sorting signals (as found in the transferrin receptor) are bound directly by the $\mu 2$ subunit (Ohno *et al.*, 1995), whereas [DE]XXXL[LIM] dileucine signals are recognized by a functional hemicomplex of the α and $\sigma 2$ subunit (Janvier *et al.*, 2003; Coleman *et al.*, 2005; Chaudhuri *et al.*, 2007). Various assembly protein and clathrin associations are established through the α and $\beta 2$ appendages (Wang *et al.*, 1995; McPherson and Ritter, 2005; Traub, 2005; Edeling *et al.*,

This article was published online ahead of print in *MBC in Press* (<http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E08-07-0712>) on October 8, 2008.

[†] These authors contributed equally to this work.

[‡] Present address: Department of Medicine and Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, MO 63110.

Address correspondence to: Linton M. Traub (traub@pitt.edu).

Abbreviations used: ARH, autosomal recessive hypercholesterolemia protein; CLASP, clathrin-associated sorting protein; Dab2, disabled-2; EGFP, enhanced green fluorescent protein; GPCR, G protein-coupled receptor; HC, heavy chain; LDL, low-density lipoprotein; mAb, monoclonal antibody; MPR, cation-independent mannose 6-phosphate receptor; PtdIns(4,5)P₂, phosphatidylinositol 4,5-bisphosphate; PTB, phosphotyrosine binding; tdRFP, tandem dimer tomato; Tf488, transferrin conjugated to Alexa Fluor 488; Tf568, transferrin conjugated to Alexa Fluor 568; Tf633, transferrin conjugated to Alexa Fluor 633; YFP, yellow fluorescent protein.

2006b; Schmid and McMahon, 2007). The α appendage has two interaction surfaces, one each upon the platform and sandwich subdomains. The platform site can bind to DP[WF] and FXDXF interaction motifs (Brett *et al.*, 2002; Praefcke *et al.*, 2004), whereas the sandwich site engages the WXX[FW]X_n[DE] motif (Mishra *et al.*, 2004; Praefcke *et al.*, 2004; Ritter *et al.*, 2004; Walther *et al.*, 2004). These short interaction sequences are typically positioned within tracts of intrinsically unstructured polypeptide, and proteins bearing the former class of motifs are typically involved in cargo selection and lattice polymerization. Proteins bearing the latter set generally include regulatory proteins such as adaptor-associated kinase 1, cyclin G-dependent kinase, and the phosphoinositide polyphosphatase synaptojanin 1 (Jha *et al.*, 2004; Praefcke *et al.*, 2004; Walther *et al.*, 2004). Some of the regulatory proteins, such as synaptojanin 1, also contain platform binding sites, potentially allowing them to compete previously bound clathrin-associated sorting proteins (CLASPs) off AP-2 (Mishra *et al.*, 2004; Praefcke *et al.*, 2004). Thus, the α appendage regulates the temporal organization of the developing clathrin lattice through binding sites that permit the recruitment of first lattice assembly and cargo selective factors, followed by regulatory proteins that control bud formation and likely promote release of proteins from AP-2 once their role in endocytosis is complete.

Similar to the α appendage, the structurally related β appendage also contains two interaction surfaces, one surface analogous to the α appendage-platform site, and one surface positioned on the opposite side from the cognate α appendage-sandwich site (Edeling *et al.*, 2006a; Schmid *et al.*, 2006). The contact sites on the β appendage do not seem to control accessory proteins in precisely the same manner as the hierarchical α appendage binding sites. Biochemical studies suggest the β appendage-platform site is largely dedicated to CLASPs, such as the β -arrestins, which concentrate G protein-coupled receptors (GPCRs) (Kim and Benovic, 2002; Laporte *et al.*, 2002; Milano *et al.*, 2002); the autosomal recessive hypercholesterolemia (ARH) protein, which decodes the FXNPXY-type sorting signal (He *et al.*, 2002; Mishra *et al.*, 2002b); and epsin 1, which recognizes poly/multiubiquitinated cargo (Barriere *et al.*, 2006; Hawryluk *et al.*, 2006). These discrete classes of cargo internalization signal do not bind directly to AP-2. The β appendage-sandwich site, along with a type I clathrin box in the β -hinge, allows AP-2 to polymerize clathrin and regulate eps15 positioning within the assembling lattice (Cupers *et al.*, 1998; Owen *et al.*, 2000; Edeling *et al.*, 2006a). Thus, the β subunit contains functionally distinct binding sites that could simultaneously allow privileged access of certain CLASPs to the lattice along with clathrin recruitment. Overall, AP-2 acts as a master adaptor, binding to the plasma membrane, sorting YXX Φ - and [DE]XXXL[LIM]-bearing cargo, and coordinating clathrin vesicle formation while simultaneously providing access for alternative types of cargo by scaffolding CLASPs. Accordingly, targeted gene disruption or mutation of AP-2 μ 2 or α subunit genes is homozygous lethal in mice (Mitsunari *et al.*, 2005), *Drosophila* (Gonzalez-Gaitan and Jackle, 1997), and *Caenorhabditis elegans* (Shim and Lee, 2000).

In humans, inherited deficiency of one CLASP, ARH, results in a pathological hypercholesterolemia similar to, but less severe than, familial hypercholesterolemia (Eden *et al.*, 2001; Garcia *et al.*, 2001). Structurally, ARH contains a phosphotyrosine binding (PTB) domain that binds simultaneously to both FXNPXY peptides and PtdIns(4,5)P₂ and an unstructured C terminus containing a type I clathrin box and the β 2 appendage-binding sequence (Eden *et al.*, 2002;

He *et al.*, 2002; Mishra *et al.*, 2002b). Functionally, it may play an analogous role to the β -arrestins, which use a related, helical [DE]_nX₁₋₂FXX[FL]XXXXR β 2-binding sequence to usher GPCRs to preformed clathrin coats (Laporte *et al.*, 2000; Kim and Benovic, 2002; Milano *et al.*, 2002; Edeling *et al.*, 2006a; Hamdan *et al.*, 2007). ARH may likewise use primarily the β 2 appendage-binding site, rather than the clathrin box, to shuttle or retain low density lipoprotein (LDL) receptors in clathrin structures.

To test ARH dependence on β 2 appendage binding, we replaced endogenous AP-2 β 2 subunits with various β 2-yellow fluorescent protein (YFP) mutants by using RNA interference (RNAi). When characterizing the β 2 subunit knockdown necessary for this approach, we found that simultaneous depletion of the β 1 subunit from the related *trans*-Golgi network (TGN)/endosome-localized AP-1 complex is also necessary, because, otherwise, the highly related, endogenous β 1 subunit compensates for β 2 subunit depletion. In the context of a β 1 + β 2 subunit knockdown, the β 2 subunit trunk is sufficient to rescue known AP-2 knockdown phenotypes (Hinrichsen *et al.*, 2003; Motley *et al.*, 2003), clustering transferrin in clathrin coats and restoring cellular AP-2 levels, although ARH surface localization is clearly disrupted. Rescue of the β 1 + β 2 subunit knockdown with a full-length β 2-YFP bearing a point mutation in the β 2-platform subdomain also fails to recover ARH localization to clathrin structures, whereas both wild-type β 2-YFP or β 2-YFP lacking clathrin binding sites restore ARH localization to clathrin puncta. This suggests that AP-2 is vital both as the YXX Φ -selective CLASP and as a scaffold controlling endocytic protein recruitment to clathrin-coated pits during endocytosis.

MATERIALS AND METHODS

Plasmids, Small Interfering RNA (siRNA) and Antibodies

The siRNA duplexes used target base pairs 1384-1402 of the human β 2 subunit (Huang *et al.*, 2004) (Dharmacon RNA Technologies, Lafayette, CO), base pairs 1529-1537 of the human β 1 subunit (Invitrogen, Carlsbad, CA or Dharmacon RNA Technologies), and base pairs 1052-1069 of the α subunit transcript (Dharmacon RNA Technologies) (Keyel *et al.*, 2006). All siRNA oligonucleotides were synthesized with dTdT overhangs. The β 2-YFP plasmid was a kind gift from Alexander Sorkin (University of Colorado at Denver, Aurora, CO; Sorkina *et al.*, 2002). Generation of the β 2-YFP mutants and truncation has been described previously (Keyel *et al.*, 2006). The tandem dimer tomato (tdRFP)- β -arrestin 1 was generated by first replacing enhanced green fluorescent protein (EGFP) with tdRFP (Shaner *et al.*, 2004) between the NheI and BspEI restriction sites in pEGFP-C1, followed by insertion of full-length *Bos taurus* β -arrestin 1 between XhoI and SalI sites. The β 2-YFP platform (Y888V) and sandwich (Y815A) subdomain mutants, the clathrin-box deleted (Δ LLDLD) mutant, the tdRFP- β -arrestin 1 paired I386A and V387A (IV \rightarrow AA) constitutively active mutant, and the clathrin box ³⁷⁶LIEL \rightarrow AAEA mutation or clathrin-box-deleted Δ LIELD were all generated using QuikChange mutagenesis (Stratagene, La Jolla, CA).

The anti-clathrin heavy chain (HC) monoclonal antibody (mAb) TD.1 (Nathke *et al.*, 1992) and X22 (Brodsky, 1985), the AP-1/2 β 1/ β 2 subunit mAb 100/1 (Ahle *et al.*, 1988) and affinity-purified antibody GD/1 (Traub *et al.*, 1999), the AP-2 α subunit mAb AP.6 (Chin *et al.*, 1989), the anti-AP-1 γ subunit antibody AE/1 (Traub *et al.*, 1995), the anti-AP-1 μ 1 subunit antibody RY/1 (Traub *et al.*, 1995), the anti-ARH antibody (Mishra *et al.*, 2002b), the anti-cation-independent mannose 6-phosphate receptor (MPR) antibody (Zhu *et al.*, 1999), the anti-epsin 1 polyclonal antibody (Drake *et al.*, 2000), and the anti-disabled-2 (Dab2) polyclonal antibody (Mishra *et al.*, 2002a) have been described previously. Affinity-purified anti-eps15 polyclonal was kindly provided by Ernst Ungewickell (Medizinische Hochschule Hannover, Hannover, Germany; Hinrichsen *et al.*, 2003). The anti-transferrin receptor mAb H68.4 was a gift from Ian Trowbridge (The Salk Institute, La Jolla, CA; White *et al.*, 1992), rabbit R11-29 anti-AP-2 μ 2 subunit serum was kindly provided by Juan Bonifacino (National Institutes of Health, Bethesda, MD; Aguilar *et al.*, 1997), the anti-lysosome-associated membrane protein (LAMP)-1 mAb G1/139 was kindly provided by Jack Rohrer (Zürcher Hochschule für Angewandte Wissenschaften, Wädenswil, Switzerland; Rohrer *et al.*, 1996), and anti-green fluorescent protein (GFP) polyclonal antibody B5 was generously provided by Phyllis Hanson (Washington University School of Medicine, St. Louis, MO;

Dalal *et al.*, 2004). Anti-AP-2 α subunit mAb clone 8 and the anti-AP-1 γ subunit mAb clone 88 were both from BD Biosciences Transduction Laboratories (Lexington, KY). The anti- β -arrestin polyclonal antibody was purchased from Sigma-Aldrich (St. Louis, MO), the anti-tubulin mAb E7 was from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA), and a hybridoma secreting anti-LDL receptor mAb IgG-C7 was from the American Type Culture Collection (Manassas, VA). Horseradish peroxidase-conjugated donkey anti-mouse and anti-rabbit, Cy5-conjugated goat anti-mouse, and 15-nm gold-conjugated anti-mouse secondary antibodies were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA), whereas Alexa Fluor 488 angiotensin II, Alexa Fluor 488-, and Alexa Fluor 568-conjugated goat anti-mouse and anti-rabbit secondary antibodies were obtained from Invitrogen.

Cell Culture, RNAi, and Reconstitution

HeLa SS6 cells (Elbashir *et al.*, 2001) were cultured at 37°C humidified with 5% CO₂ in DMEM supplemented with 10% fetal calf serum and 2 mM L-glutamine (Invitrogen). A line of HeLa SS6 cells stably expressing β 2-YFP was selected in the same medium supplemented with 0.5 mg/ml G-418 (Invitrogen). Analysis of these cells shows that <10% of cellular AP-2 contains the YFP-tagged β 2 subunit. Wild-type (+/+) and AP-2 β 2 subunit homozygous mutant (β 2 -/-) mouse embryonic fibroblasts were cultured in DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, and 1 \times antibiotic/antimycotic mixture (Sigma-Aldrich). β -Arrestin nullizygous mouse embryonic fibroblasts were kindly provided by Robert Lefkowitz (Kohout *et al.*, 2001). Cells were maintained in DMEM supplemented with 10% fetal calf serum and 2 mM L-glutamine. Human embryonic kidney (HEK) 293 cells stably expressing a FLAG-tagged type I angiotensin II receptor were kindly provided by Stéphane Laporte (McGill University, Montreal, Quebec, Canada), and they were cultured in Earle's minimal essential medium. RNAi and reconstitution were performed as described previously (Keyel *et al.*, 2006). For rescue experiments, 100 ng of rescue DNA was included along with the siRNA duplexes at the time of transfection and did not block RNAi-mediated knockdown of the targeted proteins (Supplemental Figure S2).

Immunofluorescence

HeLa SS6 cells were prepared for immunofluorescence as described previously (Mishra *et al.*, 2005). To visualize only the plasma membrane associated clathrin, or only AP-2 with the anti- β 1/ β 2 antibody GD/1, cells were treated with 10 μ g/ml brefeldin A (Epicenter Technologies, Madison, WI) for 15 min, followed by permeabilization in 0.3% saponin, 25 mM HEPES-KOH, pH 7.2, 125 mM potassium acetate, and 5 mM magnesium acetate for 1 min on ice before fixation to remove cytosolic and ARF-dependent clathrin and AP-1. For experiments involving LDL receptors, the cells were grown in DMEM supplemented with 10% lipoprotein-deficient serum (Cocalico Laboratories, Reamstown, PA), 2 mM L-glutamine for 24–48 h to up-regulate LDL receptors, whereas for experiments involving transferrin, cells were placed in DMEM supplemented with 25 mM HEPES-KOH, pH 7.2, and 0.5% bovine serum albumin (starvation medium) for 1 h before experiments to unload the receptors. To measure surface levels of receptors, cells were incubated with either the appropriate antibody or 25 μ g/ml transferrin conjugated to Alexa Fluor 568 (Tf568) (Invitrogen) in starvation medium for 1 h on ice at 4°C and fixed for immunofluorescence. To measure the amount of internalized receptors, cells were either incubated on ice as described above and then washed and warmed to 37°C for 15 min before fixation (see Figures 1 and 7); or after the 1 h in starvation medium, maintained in the continuous presence of 25 μ g/ml Tf568 or 50 μ g/ml Tf633 (Invitrogen) for 15 min at 37°C before fixation (see Figures 6 and 7). Alexa 488-labeled angiotensin II (100 nM) was added at 37°C for 5 or 20 min. For imaging of surface transferrin receptor-labeled fibroblasts, 25 μ g/ml Tf488 was bound at 4°C for 1 h in starvation media. Cells were washed once and imaged at 4°C in starvation media using a temperature-controlled stage mount (Harvard Apparatus, Holliston, MA).

Immunoprecipitation

HeLa SS6 cells grown in six-well plates, treated or untreated with siRNA against β 2 subunit as described above, were trypsinized, washed in phosphate-buffered saline (PBS), and lysed in 10 mM HEPES-KOH, pH 7.2, 0.3 M sucrose, 1% Triton X-100, and Complete mini-protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) for 30 min on ice. Cell debris was removed by centrifugation at 18,000 \times g_{max} for 10 min at 4°C, and the supernatants frozen on dry ice and stored at -80°C until use. The samples were thawed and incubated with 2 μ g of anti- α subunit mAb AP.6 for 1 h at 4°C with gentle shaking, followed by the addition of protein G-coupled beads (Sigma-Aldrich), an additional hour at 4°C with gentle shaking, and then centrifugation to separate supernatant from pellet. The pellets were washed extensively in PBS and 1% Triton X-100, and then they were mixed with SDS sample buffer such that one-eighth of the pellet and ~1/25 of the supernatant were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE). AP-2 was similarly immunoprecipitated from lysates of embryonic fibroblasts prepared in 10 mM HEPES-KOH, pH 7.2, 0.3 M sucrose, 500 mM Tris-HCl, 1% Triton X-100, Complete mini-protease inhibitor cocktail, and 1 mM phenylmethylsulfonyl fluoride. After centrifugation to remove insoluble material, lysates

were diluted fourfold before addition of 5 μ g of mAb AP.6. Electrophoresis and immunoblotting was as described previously (Keyel *et al.*, 2006). Blots were quantitated by measuring the integrated intensity of a fixed region containing the band in MetaMorph (MDS Analytical Technologies, Sunnyvale, CA), subtracting that intensity from the background in a similarly sized region, and normalizing expression to clathrin expression. Normalized expression levels were compared with those of mock-transfected cells to determine up- or down-regulation of AP-1 and AP-2 subunits under the various RNAi conditions.

Microscopy

Images were acquired on a FluoView FV500 or FV1000 confocal microscope (Olympus, Tokyo, Japan) as described previously (Keyel *et al.*, 2006). Quantitation of ARH clathrin coat localization was performed using MetaMorph software (MDS Analytical Technologies) by measuring the integrated intensity of ARH staining in cell surface confocal sections that were either control (normal transferrin internalization), knocked down (blocked transferrin internalization), or rescued (YFP expression) and subtracting the intensity of knockdown cells from that of either mock transfected or neighboring rescued cells. The number of clathrin and AP-2 (α subunit) puncta were determined by manually counting all puncta within a 10 \times 10 μ m (clathrin) or 6 \times 6 μ m (AP-2) portion of cells from multiple fields and independent experiments expressing very low levels of clathrin/AP-2 (AP-2 knocked down cells) or cells expressing wild-type levels of the protein (mock). Statistical significance was determined using Student's *t* test. Cells with surface transferrin, transferrin uptake or AP-2 (α subunit) intensity phenotypes were manually counted in MetaMorph (MDS Analytical Technologies) as either normal or impaired, and the total percentage of cells either expressing or not expressing β 2-YFP determined. Impaired phenotypes consisted of loss of transferrin localization to coated pits, very low levels of internalized transferrin, or AP-2 α subunit intensities on a par with those found with AP-2 α subunit siRNA. These percentages were averaged for two to three independent experiments and significance determined using a one-tailed Student's *t* test.

Total internal reflection fluorescence microscopy (TIR-FM) was performed as described previously (Keyel *et al.*, 2004), with some modifications. Images were collected with a thermoelectrically cooled Cascade II 512 camera (Photometrics, Tucson, AZ). Data sets were collected with MetaMorph software at ~1 frame/5 s. For quantification of colocalization of tdRFP- β -arrestin 1 with AP-2 in β 2-YFP-expressing cells, an average of 55 spots/cell in 11-15 individual cells were analyzed.

Adherent plasma membrane from cells treated with α subunit siRNA as described above were prepared for rapid-freeze, deep-etch electron microscopy as described previously (Heuser, 2000). Briefly, cells grown on small oriented pieces of glass coverslip were disrupted by sonication, fixed in paraformaldehyde, and labeled with anti-transferrin receptor mAb H68.4 and then 15-nm gold-conjugated anti-mouse antibody before flash freezing in liquid helium (Keyel *et al.*, 2006).

RESULTS

Gene Silencing of the AP-2 α Subunit

In HeLa SS6 cells, we find transfection of siRNA duplexes targeting the AP-2 α subunit mRNA reduces the protein level of all four adaptor subunits >75% within 48 h (Figure 1A and Supplemental Figure 1A), in very good agreement with previous results (Hinrichsen *et al.*, 2003; Motley *et al.*, 2003). Depletion of AP-2 is also seen morphologically, as a sharp decrease in the intensity of surface AP-2-positive puncta compared with the control cells (Figure 1B). It is known that AP-2 knockdown reduces the amount of clathrin positioned at the plasma membrane but not that recruited to other structures or total cytoplasmic amounts (Hinrichsen *et al.*, 2003; Motley *et al.*, 2003). To selectively visualize clathrin at the plasma membrane, we briefly treated cells with brefeldin A to dissociate clathrin from internal membrane structures, and then we rapidly permeabilized the cells before fixation (Figure 1, C and D). In mock-transfected cells, this treatment effectively eliminates TGN, endosomal and cytosolic clathrin, without perturbing the plasma membrane associated clathrin pool. No AP-1 γ subunit staining is observed, and the remaining β subunit signal is fully sensitive to α subunit RNAi (Figure 1C). Although the total amount of clathrin recruited to the plasma membrane is greatly diminished upon AP-2 α subunit RNAi (Figure 1D), we do not observe that the total number of surface puncta decreases




Figure 1. siRNA-mediated gene silencing of the AP-2 α subunit. (A) Lysates of HeLa SS6 cells untreated (lanes a and b) or treated with AP-2 α subunit siRNA (lanes c and d) were resolved by SDS-PAGE and either Coomassie stained or transferred to nitrocellulose. Sections of the blots were probed with anti-AP-2 α subunit mAb clone 8, anti-clathrin heavy chain (HC) mAb TD.1, anti- β 1/ β 2 subunit mAb 100/1, anti-AP-2 μ 2 antiserum, or anti-tubulin mAb E7, and only the relevant portion of each blot shown. The position of molecular mass standards (in kilodaltons) is indicated on the left. (B–D) HeLa SS6 cells untreated (left) or treated with AP-2 α subunit siRNA (right) were treated with 10 μ g/ml brefeldin A for 15 min, permeabilized on ice for 1 min before fixation, and prepared for immunofluorescence using the anti-AP-2 α subunit mAb AP.6 (B), anti-AP-1 γ subunit mAb (C; green), anti- β 1/ β 2 subunit antibody GD/2 (C; red), or anti-clathrin heavy chain mAb X22 (D). (E–G) HeLa SS6 cells untreated (left) or treated with AP-2 α subunit siRNA (right) were incubated on ice for 1 h with either anti-LDL receptor mAb C7 (E; green), Tf568 (E, red and F), anti-LAMP-1 mAb (G; green), or anti-MPR antibody (G; red) and fixed (E and G) or washed and warmed to 37°C for 15 min and fixed (F) followed by indirect immunofluorescence. Bar, 10 μ m.

>10-fold as reported originally (Hinrichsen *et al.*, 2003; Motley *et al.*, 2003). Rather, in α subunit-silenced cells, although very dim, the number of discrete clathrin- and AP-2-containing surface structures is 73.2 and 70.7% that of control, respectively. The discrepancy is probably because AP-2 complexes are not completely eliminated under our single transfection RNAi conditions (Figure 1B).

Extinguishing AP-2 expression also abrogates the clustering of surface receptors bearing a YXX Φ internalization signal, exemplified by the transferrin receptor, at clathrin-positive puncta. Unlike the mock-treated cells, transferrin marks a population of diffuse receptors on the surface of AP-2-deficient cells (Figure 1E). Other receptors, such as the LDL receptor, that bear the FXNPXY-type internalization signal decoded by the CLASPs ARH and disabled-2 (Dab2), can internalize in an AP-2-independent manner (Eden *et al.*, 2002; Garuti *et al.*, 2005; Keyel *et al.*, 2006; Maurer and Cooper, 2006; Eden *et al.*, 2007). Nonetheless, because Dab2 and ARH each bind physically to both AP-2 and clathrin, in mock-treated cells, the LDL receptor and transferrin congregate in common surface structures (Figure 1E), which contain clathrin and AP-2 (Keyel *et al.*, 2006). Yet, when AP-2 complexes are extinguished, only the surface distribution of the transferrin receptor, and not the LDL receptor, alters dramatically (Figure 1E). A consequence of the dispersion of the transferrin receptor is that transferrin is very poorly

internalized (Figure 1F). To verify that the internalization defect is general to proteins bearing the YXX Φ signal, we examined the surface distributions of the MPR and LAMP-1. The trafficking trajectory of these transmembrane proteins takes them through the plasma membrane relatively infrequently (Rohrer *et al.*, 1996) and normally, the proteins are concentrated, at steady state, in endosomes/TGN and lysosomes, respectively. If delivered to the cell surface, both are retrieved via clathrin-mediated endocytosis (Ghosh *et al.*, 2003). In the context of α subunit knockdown, and consistent with both the absolute dependence of the YXX Φ signal on AP-2 for sorting into clathrin-coated vesicles and previous observations (Harasaki *et al.*, 2005; Janvier and Bonifacio, 2005), a surface population of both the MPR and LAMP-1 becomes readily detectable as they stagnate at the surface (Figure 1G).

To better understand at the ultrastructural level how the AP-2 knockdown affects clathrin lattice assembly at the cell surface, adherent plasma membranes of mock- and α subunit siRNA-treated cells were analyzed by immunogold freeze-etch electron microscopy. AP-2 knocked down cells can be unambiguously identified with mAb H68.4. This antibody detects an epitope located near the amino terminus of the human transferrin receptor that overlaps with the YTRF internalization signal (White *et al.*, 1992). Transferrin receptors positioned within clathrin lattices by engagement




Figure 2. AP-2 knocked down cell ultrastructure. HeLa SS6 cells either mock transfected (A) or transfected with α subunit siRNA oligonucleotides (B–D) were briefly sonicated to prepare cell cortices, fixed, labeled with anti-transferrin receptor mAb H68.4, and then 15-nm gold-conjugated anti-mouse secondary antibodies to visualize extra-lattice receptors. Arrows indicate gold-labeled receptors.

of the AP-2 μ 2 subunit are not recognized by this mAb; only the extra-lattice population of the receptor is detected (White *et al.*, 1992). In our images, compared with mock-transfected cells (Figure 2A), the frequency of gold labeling in the AP-2 gene-silenced cells is increased, especially the population >100 nm from assembled clathrin lattices (Figure 2, B–D). In the siRNA-transfected cells, the discernible clathrin coats are substantially smaller than normal (Motley *et al.*, 2003), concordant with the immunofluorescence data (Figure 1) and the capability of CLASPs like Dab2 and epsin to promote clathrin lattice assembly (Drake *et al.*, 2000; Morris and Cooper, 2001; Kalthoff *et al.*, 2002; Mishra *et al.*, 2002a). Despite the limited dimensions, both flattened lattices and invaginating buds are visible. Overall, we conclude that the knockdown of the α subunit of AP-2 ablates AP-2 sorting activity with similar functional consequences as reported initially (Hinrichsen *et al.*, 2003; Motley *et al.*, 2003), except that our knockdown procedure does not decrease as dramatically the total number of surface clathrin-containing structures.

Gene Silencing of the AP-2 β 2 Subunit Does Not Inactivate AP-2

Next, as a prelude to evaluating the function of the β 2 subunit hinge and appendage by reconstitution after AP-2 RNAi, we selectively knocked down the AP-2 β 2 subunit in HeLa SS6 cells. Although the β 2 subunit polypeptide is very effectively diminished (Huang *et al.*, 2004), in marked contrast to the α subunit RNAi, the abundance of other AP-2 subunits is only mildly affected (Figure 3A and Supplemental Figure S1A). A comparatively weak effect on AP-2 levels

is also apparent by immunofluorescence. The levels of the α , and, surprisingly, β subunits of AP-2 in the context of a β 2 subunit knockdown are reduced from normal levels, but clearly not to the extent observed in an α subunit knockdown (Figure 3B). Likewise, the other phenotypes characteristic of α subunit knockdown are not as penetrant when using β 2 subunit siRNA duplexes (Figure 3, C–E). The intensity of clathrin within punctate structures is intermediate between control and α subunit knockdown, which is likely due to the presence of functional AP-2 complexes in the cell (Figure 3C). Also, AP-2-dependent cargo, the MPR and LAMP-1, do not accumulate appreciably at the cell surface (Figure 3D), and although the transferrin distribution is more diffuse over the surface than in mock-transfected cells, it is also present in numerous puncta on the plasma membrane (Figure 3E). We conclude that AP-2 β 2 subunit knockdown produces a milder variant of the α or μ 2 subunit RNAi phenotype, due to incomplete depletion of AP-2.

The AP-1 β 1 Subunit Is Incorporated into AP-2 in the Absence of a β 2 Subunit

A clue to the biochemical basis for the milder β 2 RNAi phenotype comes from the surface β subunit signal in cells lacking the β 2 subunit (Figure 3B). The β 1 and β 2 subunits of AP-1 and AP-2 are ~85% identical, in contrast to the other three subunits of the heterotetramers, which display <50% homology (Figure 4A). The appendages of the β 1 and β 2 subunits are structurally homologous and share many binding partners (Owen *et al.*, 2000; Lundmark and Carlsson, 2002; Edeling *et al.*, 2006a; Kneuhl *et al.*, 2006; Schmid *et al.*,




Figure 3. AP-2 $\beta 2$ subunit gene silencing. (A) Lysates of HeLa SS6 cells untreated (lane a) or treated with either AP-2 α or $\beta 2$ subunit siRNA (lanes b and c) were resolved by SDS-PAGE and either Coomassie stained or transferred to nitrocellulose. Sections of the blots were probed with anti-clathrin HC mAb TD.1, anti-AP-2 α subunit mAb clone 8, anti- $\beta 1/\beta 2$ subunit mAb 100/1, anti-AP-2 $\mu 2$ antiserum, or anti-AP-1 γ subunit antibody AE/1, and only the relevant portion of the blots is shown. The position of molecular mass standards (in kilodaltons) is indicated on the left. (B and C) HeLa SS6 cells untreated (left) or treated with AP-2 α - (middle), or $\beta 2$ subunit siRNA (right) were treated with 10 $\mu\text{g}/\text{ml}$ brefeldin A for 15 min, permeabilized on ice for 1 min before fixation, and prepared for immunofluorescence using the anti-AP-2 α subunit mAb AP.6 (B, green), anti- $\beta 1/\beta 2$ subunit antibody GD/2 (B; red), or anti-clathrin HC mAb X22 (C). (D and E) HeLa SS6 cells untreated (left) or treated with AP-2 α (middle) or $\beta 2$ subunit (right) siRNA were incubated on ice for 1 h with either anti-LAMP-1 mAb (D; green) and anti-MPR antibody (D; red), or anti-LDL receptor mAb C7 (E; green) and Tf568 (E; red), fixed, and prepared for indirect immunofluorescence. The inset in E shows Tf568 immunofluorescence from each sample.

2006). In fact, the *Drosophila melanogaster* genome encodes only a single β subunit that is incorporated into both AP-1 and AP-2 (Camidge and Pearse, 1994). Almost all available antibodies raised against the vertebrate β subunits recognize both $\beta 1$ and $\beta 2$ subunits, although these subunits can be resolved by SDS-PAGE (Page and Robinson, 1995; Sorkin et al., 1995; Traub et al., 1996). Thus, the fluorescent signal observed in $\beta 2$ subunit-knockdown cells may be due to $\beta 1$

subunit incorporated into AP-2. To test this hypothesis, we treated HeLa SS6 cells with or without $\beta 2$ subunit siRNA, and then we immunoprecipitated AP-2 with an α subunit-specific mAb. In mock-transfected cells, the majority of AP-2 is recovered in the immunoprecipitate, and the principal β subunit incorporated into AP-2 is the faster migrating $\beta 2$ chain (Figure 4B). However, when the $\beta 2$ subunit is depleted, this smaller chain almost disappears, and the major-




Figure 4. β 1 subunit rescues β 2 subunit knockdown of AP-2. (A) Schematic diagram of AP-1 and AP-2 complex composition and subunit homology. (B) Lysates from either untreated or β 2 siRNA-treated HeLa SS6 cells were prepared and AP-2 immunoprecipitated using the anti- α subunit mAb AP.6. Aliquots of the supernatant and precipitate fractions from both control and β 2 RNAi samples were resolved by SDS-PAGE and transferred to nitrocellulose. Blots were probed with the anti-AP-2 α subunit mAb clone 8, anti- β 1/ β 2 subunit antibody mAb 100/1, anti-clathrin HC antibody mAb TD.1, or anti-AP-2 μ 2 antiserum, and only the relevant portion of each blot is shown.

ity of the β subunit now assembled into AP-2 is the larger β 1 subunit (Figure 4B).

Independent verification of the incorporation of the AP-1 β 1 subunit into AP-2 comes from mouse embryonic fibroblasts homozygous for a disrupted β 2 subunit gene. Like HeLa SS6 cells, +/+ fibroblasts from normal littermate controls display both the β 1 subunit and the faster migrating β 2 polypeptide (Figure 5A). The β 2-null -/- fibroblasts clearly express only the larger β 1 polypeptide, and the overall abundance of the AP-2 α and μ 2 subunits, but not of the AP-1 μ 1 or σ 1 subunits, is diminished compared with the control lysates. AP-2 immunoprecipitated from -/- cells with an α subunit-specific mAb contains only the β 1 subunit (Figure 5A), similar to the β 2 gene-silenced HeLa SS6 cells. Likewise, the surface distribution of AP-2, as judged by the intracellular positioning of the α subunit, is very similar to the +/+ fibroblasts (Figure 5, B-E), despite the reduced levels of the α and μ 2 chains in the -/- fibroblasts. The surface distribution of CLASPs such as Dab2, epsin, and eps15 is also highly similar to the normal fibroblast controls (Figure 5, C-E). Therefore, we conclude that because of the high degree of sequence homology, the β 1 subunit is promiscuously incorporated into AP-2 when cellular β 2 subunit levels are depressed, and that this misassembly largely preserves the functional capabilities of the AP-2 heterotetramer. Interestingly, this substitution phenomenon does occur naturally to a limited extent, as incorporation of endogenous β 2 into AP-1 in brain and β 1 into AP-2 in liver has been documented (Page and Robinson, 1995; Sorkin *et al.*, 1995; Traub *et al.*, 1996), and some β 1 subunit is present in AP-2 immunoprecipitated from +/+ fibroblasts (Figure 5A).

Simultaneous Knockdown of β 1 and β 2 Subunits Functionally Ablates AP-2

Because gene silencing of the β 2 subunit alone is insufficient to reduce AP-2 levels and disrupt sorting, we designed an siRNA duplex to extinguish the β 1 subunit. Transfection of this duplex selectively targets the β 1 subunit, and together the β 1 + β 2 subunit siRNAs silence both AP-1 and AP-2 (Figure 6A). Furthermore, the combined β 1 + β 2 RNAi reproduces the α subunit knockdown phenotype (Figure 6, B-D). Morphologically, the level of the AP-2 α subunit is decreased by β 1 + β 2 subunit RNAi similar to that observed with an α subunit knockdown (Figure 6B), and the amount of clathrin deposited on the plasma membrane is reduced to that observed with the α subunit RNAi (Figure 6C). Most

importantly, transferrin receptor internalization is strongly blocked and fluorescent transferrin accumulates in a diffuse pattern over the cell surface (Figure 6D). Thus, simultaneous knockdown of both β 1 and β 2 subunits functionally incapacitates AP-2 and phenocopies AP-2 α or μ 2 subunit ablation.

Functional Reconstitution of AP-2 with β 2-YFP

To begin to probe the function of the β 2 subunit *in vivo* then, an siRNA-insensitive β 2 subunit fused at the carboxy terminus to YFP (β 2-YFP) (Sorkina *et al.*, 2002; Hamdan *et al.*, 2007) was ectopically expressed in HeLa SS6 cells also transfected with the β 1 + β 2 subunit-silencing duplexes. The transiently expressed β 2 construct (Figure 7A) clearly reconstitutes AP-2 function successfully; the ectopic β 2-YFP targets to α subunit puncta in control cells, and restores normal concentration of surface transferrin at clathrin-coated structures in β 1 + β 2 subunit knockdown cells (Figure 7, B and C). Approximately 95% of β 2-YFP-expressing cells display clustered transferrin, whereas <30% of the non-GFP-producing cells have similar patches of the ligand (Supplemental Figure S1B). Expression of the plasmid-borne YFP-tagged β 2 subunit in some siRNA-treated cells is confirmed by immunoblot (Figure 7A). The relatively low level of β 2-YFP expression (reflecting the transfection efficiency) concurs with another recent study dealing with re-expression of a GFP-tagged AP-2 α subunit after RNAi (Rappoport and Simon, 2008). Transfected cells have apparently normal AP-2 levels, as seen by immunofluorescence, and permit efficient transferrin internalization (Figure 7D); only ~20% of β 1 + β 2 RNAi-treated cells not expressing GFP show bright AP-2-positive puncta compared with ~70% of cells synthesizing β 2-YFP (Supplemental Figure S1B). Importantly, transferrin uptake is not the result of reduced siRNA transfection efficiency due to the simultaneous addition of β 2-YFP plasmid DNA during RNAi treatment. Adding similar amounts of control GFP plasmid DNA restores neither AP-2 levels nor the punctate surface transferrin localization (Supplemental Figure S2). Therefore, the β 2-YFP seems to functionally reconstitute AP-2 in β 1 + β 2 subunit knocked down cells. Fused to YFP, a β 2 subunit trunk that lacks the C-terminal hinge and appendage, also targets to transferrin-positive puncta in control cells (Figure 7E), and it promotes the clustering of surface transferrin at YFP-positive patches, as opposed to the diffuse distribution of transferrin in neighboring β 1- + β 2-extinguished cells (Figure 7F).




Figure 5. Stable incorporation of the $\beta 1$ subunit into AP-2 in $\beta 2$ subunit-null mouse fibroblasts. (A) Aliquots of lysates from either control $+/+$ (lane a) or $\beta 2$ -null $-/-$ (lane c) mouse embryonic fibroblasts and of mAb AP.6 immunoprecipitates from the $+/+$ (lane b) or $-/-$ (lane d) lysates were resolved by SDS-PAGE and transferred to nitrocellulose. Blots were probed with anti-clathrin HC mAb TD.1 and affinity purified anti- $\beta 1/\beta 2$ subunit polyclonal GD/1, anti-AP-2 α subunit mAb clone 8, anti-AP-2 $\mu 2$ subunit antiserum, or affinity-purified anti- $\mu 1$ subunit polyclonal RY/1, and only the relevant portion of each blot is shown. The asterisk indicates a nonspecific band. Loss of $\beta 2$ -chain expression results in a compensatory increase in the steady-state level of the $\beta 1$ subunit in the cultured fibroblasts, although the level of AP-2 is nevertheless reduced compared with wild-type fibroblasts. (B–E) Wild-type ($+/+$; left column) or $\beta 2$ -null ($-/-$; right column) mouse embryonic fibroblasts were fixed and labeled with Hoechst 33258, anti- α subunit mAb AP.6 and either anti- $\beta 1/\beta 2$ subunit GD/1 (B), anti-Dab2 (C), anti-epsin (D), or anti-eps15 (E) polyclonal antibodies. Representative confocal sections of the ventral plasma membrane are shown. In all cases, absence of $\beta 2$ does not obviously perturb the punctate patterning of the α subunit or CLASPs. Bar, 10 μm .

ARH Requires the $\beta 2$ Appendage for Clathrin Coat Localization

Next, we examined the effects the $\beta 1 + \beta 2$ subunit knock-down has on the distribution of the $\beta 2$ subunit binding partner ARH. ARH uses a helically structured $[\text{DE}]_n\text{X}_1\text{-}_2\text{FXX}[\text{FL}]\text{XXXR}$ motif to engage the platform site on the $\beta 2$ appendage (Edeling *et al.*, 2006a; Schmid *et al.*, 2006). Knock-down of the $\beta 1 + \beta 2$ subunits reduces the amount of ARH localized to clathrin-coated structures (Figure 8). This can be reversed by expression of the $\beta 2$ -YFP, but not $\beta 2$ -YFP_{TRNK} lacking both the unstructured hinge and appendage domains (Figure 8, A and B). This failure to rescue is due solely to lack of a functional platform binding site, as expression of $\beta 2$ -YFP bearing the platform site-disrupting Y888V mutation fails to restore ARH localization, but simultaneous deletion of the clathrin box and introduction of the sandwich site disrupting Y815A mutation into $\beta 2$ -YFP reconstitutes ARH positioning in clathrin coats (Figure 8, C and D). Measurement of the difference in fluorescence intensity between transfected cells and neighboring knockdown cells demonstrates that the AP-2 dependence of ARH coated-structure localization is wholly dependent on the $\beta 2$ appendage platform site (Figure 8E). We conclude that in vivo ARH requires the $\beta 2$ appendage binding sequence to efficiently target to clathrin coats to promote efficient sorting of LDL receptors.

Clathrin Binding Surface on the $\beta 2$ Subunit Appendage

In addition to engaging ARH and β -arrestins, the $\beta 2$ subunit appendage also binds physically to clathrin (Owen *et al.*, 2000; Lundmark and Carlsson, 2002; Edeling *et al.*, 2006a; Kneuhl *et al.*, 2006; Schmid *et al.*, 2006). Yet, the precise molecular basis for this association is currently controversial. There is general agreement that by binding bivalently to the clathrin heavy chain, some $\beta 2$ subunit partners could be controlled spatiotemporally as the extent of polymerized clathrin lattice increases (Edeling *et al.*, 2006a; Kneuhl *et al.*, 2006; Schmid *et al.*, 2006; Schmid and McMahon, 2007; Ungewickell and Hinrichsen, 2007). We recently mapped the clathrin binding surface to a site, including Tyr815, on the N-terminal sandwich subdomain (Edeling *et al.*, 2006a), and our prior results indicate that clathrin binding to the $\beta 2$ appendage sandwich can displace interaction partners such as eps15 and AP180, which bind to the same site. Because clathrin trimers stoichiometrically outnumber AP-1/2 in preparations of biochemically purified clathrin-coated vesicles (Blondeau *et al.*, 2004; Girard *et al.*, 2005), the excess of clathrin heavy chain terminal domains, which project into the interior of the assembled coat (Musacchio *et al.*, 1999; Edeling *et al.*, 2006b), can bind avidly to AP-2 through the $\beta 2$ subunit. Indeed, we (Edeling *et al.*, 2006a) and others (Tebar *et al.*, 1996) localize eps15 to only the periphery of clathrin-coated structures. Similar conclusions have been drawn for the mode of engagement of the monomeric GGA adaptor proteins and clathrin, where the C-terminal GAE domain of the GGAs only contains a sandwich subdomain (Kneuhl *et al.*, 2006). Because activation of GPCRs leads to the rapid translocation of an activated GPCR- β -arrestin complex to pre-existing clathrin-coated structures at the cell surface (Laporte *et al.*, 2000; Santini *et al.*, 2002; Scott *et al.*, 2002), and because ARH (Figure 8; He *et al.*, 2002; Mishra *et al.*, 2002b) and β -arrestins (Kim and Benovic, 2002; Laporte *et al.*, 2002) specifically engage the platform subdomain of the $\beta 2$ appendage, we proposed that the $\beta 2$ platform interaction surface represents a relatively privileged binding site (Mishra *et al.*, 2005; Brett and Traub, 2006; Edeling *et al.*, 2006a). Chal-





Figure 6. $\beta 1 + \beta 2$ subunit RNAi recapitulates α subunit RNAi phenotype. (A) Lysates of HeLa SS6 cells untreated (lane a) or treated with either AP-1 $\beta 1$ (lane b), AP-2 $\beta 2$ (lane c), or $\beta 1 + \beta 2$ subunit siRNAs (lane d) were resolved by SDS-PAGE and either Coomassie stained or transferred to nitrocellulose. Sections of the blots were probed with the anti-clathrin HC mAb TD.1 and anti- $\beta 1/\beta 2$ subunit mAb 100/1, anti-AP-2 α subunit mAb clone 8, anti-AP-2 $\mu 2$ subunit antiserum, anti-AP-1 γ subunit antibody AE/1, or anti-AP-1 $\mu 1$ subunit antibody RY/1 polyclonal antibodies, and only the relevant portions are shown. The position of molecular mass standards (in kilodaltons) is indicated on the left. (B–D) HeLa SS6 cells were either untreated (left), treated with either AP-2 α subunit siRNA (middle), or both AP-1 $\beta 1$ and AP-2 $\beta 2$ subunit siRNA (right). Next, they were either fixed and probed with anti-AP-2 α subunit mAb AP.6 (B), brefeldin treated and permeabilized on ice before fixation and probed with anti-clathrin HC mAb X22 (C), or serum starved for 1 h, given 25 $\mu\text{g}/\text{ml}$ Tf568 continuously for 15 min at 37°C, and fixed (D). Arrowheads indicate accumulation of transferrin on the cell surface in contrast to the control cells. Bar, 10 μm .

lenging these findings and calling our conclusions “misleading,” McMahon and colleagues assert that it is the platform subdomain, and not the sandwich site, that is the location of the second point of contact between the clathrin heavy chain and the $\beta 2$ (and $\beta 1$) hinge + appendage (Schmid *et al.*, 2006; Schmid and McMahon, 2007). In this model, clathrin interference dislodges CLASPs such as β -arrestin and ARH from the $\beta 2$ appendage, but because both these proteins also have an adjacent but separate clathrin binding sequence, the proteins would remain associated with assembling clathrin coats despite occupancy of the $\beta 2$ platform with a distal leg segment of the heavy chain (Schmid *et al.*, 2006; Schmid and McMahon, 2007). This is a chief feature of the changing hubs model formulated to account for the vectorial nature of the clathrin coat assembly process (Schmid and McMahon,

2007). Clearly then, these opposing models have importantly different implications for the molecular basis of ARH- and β -arrestin-mediated cargo capture within forming clathrin coats.

To attempt to distinguish between the two models, we used a mutant form of β -arrestin 1. Wild-type β -arrestins remain diffusely cytosolic in the absence of GPCR stimulation (Laporte *et al.*, 2000; Santini *et al.*, 2002; Scott *et al.*, 2002) (Figure 9A) by maintaining a basal, inactive conformation. Several closely spaced residues within the C-terminal $[\text{DE}]_n\text{X}_{1-2}\text{FXX}[\text{FL}]\text{XXXR}$ motif interact with the major folded N-terminal region of β -arrestin, rigidifying the protein and attenuating the CLASPs ability to engage the assembling clathrin machinery (Kim and Benovic, 2002; Gurevich and Gurevich, 2004; Edeling *et al.*, 2006a; Burtsey *et al.*, 2007). In




Figure 7. Rescue of AP-2 knockdown with $\beta 2$ -YFP. (A) Lysates of HeLa SS6 cells untreated (lane a) or treated with either AP-2 α subunit (lane b), both AP-1 $\beta 1$ subunit and AP-2 $\beta 2$ subunit siRNA (lane c) along with full-length $\beta 2$ -YFP (lane d), or $\beta 2$ -YFP_{TRUNK} (lane e) were resolved by SDS-PAGE and transferred to nitrocellulose. Sections of the blots were probed with the anti-clathrin HC mAb TD.1 and anti- $\beta 1/\beta 2$ subunit mAb 100/1, anti-GFP antibody, anti-AP-2 α subunit mAb clone 8, anti-AP-2 $\mu 2$ subunit antiserum, or anti-AP-1 γ subunit antibody AE/1 and only the relevant portions show. (B–F) Mock-transfected (B and E) or $\beta 1 + \beta 2$ subunit siRNA-transfected (C, D, and F) HeLa SS6 cells were transfected with either full-length $\beta 2$ -YFP (B–D) or $\beta 2$ -YFP_{TRUNK} (E and F) (green in merged images), and either surface labeled with Tf568 (B, C, E, and F) (red in merged images) and fixed, or incubated with Tf568 continuously for 15 min at 37°C, fixed, and probed with anti-AP-2 α subunit mAb AP.6 (D) (blue in merged image). Note that $\beta 2$ -YFP-expressing cells cluster transferrin at the surface (C) and do not have the typical circumferential band of transferrin at 15 min (D; arrowheads) and that the $\beta 2$ -YFP_{TRUNK} restores clustering of surface transferrin receptors (F) as well. Bar, 10 μ m.

β -arrestin 1, immediately preceding the proximal Phe388 of the $\beta 2$ platform binding motif are Ile386 and Val387. Double substitution of these residues to Ala (IV \rightarrow AA) results in constitutive association of β -arrestin 1 with clathrin-coated structures in the absence of any GPCR activation (Burtey *et al.*, 2007). If β -arrestins only remain associated with surface coated structures by switching to clathrin when assembling clathrin binds the AP-2 $\beta 2$ subunit appendage, then deletion or mutation of the β -arrestin 1 clathrin box sequence ³⁷⁶LIELD should prevent the IV \rightarrow AA mutant from colocalizing extensively with clathrin-coated structures at the plasma membrane.

Using TIR-FM to inspect the ventral surface of HeLa SS6 cells stably expressing $\beta 2$ -YFP, we confirm that tDRFP- β -arrestin 1 is soluble while a portion of the IV \rightarrow AA mutant concentrates at pre-existing, $\beta 2$ subunit positive clathrin-coated structures (Figure 9, A and B) (Burtey *et al.*, 2007). In the IV \rightarrow AA background, the colocalization of neither a LIEL \rightarrow AAEA substitution nor a Δ LIELD mutant with coated structures at the plasma membrane marked by $\beta 2$ -YFP is obviously different from the protein containing an intact clathrin box (Figure 9, C and D). Although $0.6 \pm 0.3\%$ of AP-2 structures colocalize with tDRFP- β -arrestin 1, $99.1 \pm 0.6\%$ of AP-2-positive spots contain tDRFP- β -arrestin (IV \rightarrow AA). For the tDRFP- β -arrestin (IV \rightarrow AA+LIEL \rightarrow AAEA) and tDRFP- β -arrestin (IV \rightarrow AA+ Δ LIELD) mutants, $95 \pm 2\%$ and $89 \pm 3\%$ of AP-2 structures contain β -arrestin, respectively.

There are several distinct classes of clathrin-coated structures on the ventral surface of HeLa SS6 cells (Keyel *et al.*, 2004), and the IV \rightarrow AA β -arrestin 1 mutants localize to all of these. Analysis of the dynamics of de novo-forming puncta reveals that, like the tDRFP- β -arrestin 1 (IV \rightarrow AA) (Figure 10,

A–C), the IV \rightarrow AA+ Δ LIELD mutant concentrates at, and then disappears with, $\beta 2$ -YFP-tagged AP-2 structures (Figure 10 D–F). We do not observe earlier loss of the IV \rightarrow AA+ Δ LIELD tDRFP- β -arrestin 1 mutant from these patches that would indicate failure to switch to a strictly clathrin-dependent mode of association. Very similar results are obtained using BS-C-1 cells stably expressing GFP-tagged clathrin light chain (data not shown), a cell line that exhibits de novo coat formation almost exclusively (Ehrlich *et al.*, 2004).

It is important to note that in these experiments, the activation of the β -arrestin 1 (IV \rightarrow AA) mutant occurs in the absence of any GPCR ligand addition, but HeLa SS6 cells also do express endogenous β -arrestins. Although there is currently some doubt that nonvisual arrestins oligomerize at physiological concentrations (Hanson *et al.*, 2008b), overexpressed β -arrestins can form multimers (Storez *et al.*, 2005; Milano *et al.*, 2006). Oligomerization requires inositol hexakisphosphate binding and pertains to the soluble form of β -arrestin, because the contact sites for dimer and tetramer assembly are located on the concave surface that engages an activated receptor (Milano *et al.*, 2006; Hanson *et al.*, 2008a,b). Solution oligomers therefore do not bind to GPCRs, and exposure of the C-terminal region, which couples β -arrestins to the clathrin machinery, destabilizes oligomers (Hanson *et al.*, 2008a). We thus believe it unlikely that hetero-oligomerization with endogenous β -arrestins accounts for the association of the IV \rightarrow AA + clathrin box mutants with surface clathrin-coated structures. Supporting this view is that transfection of the tDRFP- β -arrestin 1 (IV \rightarrow AA) clathrin-binding mutants into β -arrestin 1/2 nullizygous fibroblasts (Kohout *et al.*, 2001) still results in constitutive




Figure 8. ARH requires the β 2 appendage platform for plasma membrane localization. HeLa SS6 cells transfected with β 1 + β 2 subunit siRNAs and either full-length β 2-YFP (A), β 2-YFP trunk (B), or full-length β 2-YFP bearing Y888V (C), or dual Y815A and Δ LLNLD (D) mutations (left column) were incubated with 50 μ g/ml Tf633 for 15 min at 37°C, permeabilized, fixed and stained with polyclonal anti-ARH antibodies (right column). (E) A comparison of the fluorescence intensity between β 2-YFP-transfected cells and knockdown cells (as determined by lack of Tf633 internalization) shows the differences between β 2-YFP fusions that can recruit ARH to the membrane and those that cannot. No rescue indicates the difference in ARH intensity between wild-type and β 1 + β 2 knocked down cells.

accumulation of the tagged β -arrestin at membrane puncta that are also positive for surface transferrin (Figure 11).

Finally, like the β -arrestin 1 (IV \rightarrow AA) mutant, the compound (IV \rightarrow AA+ Δ LIELD) mutant translocates rapidly to the surface of angiotensin II-stimulated HEK cells stably expressing the type I angiotensin II receptor (Figure 12). At 5 min, both the β -arrestin mutants colocalize with fluorescent angiotensin II at cell surface patches and peripheral endosomes, whereas, after 20 min, both angiotensin II and β -arrestin 1 (IV \rightarrow AA+ Δ LIELD) are found in larger, juxtanuclear endosomes, typical of a class B GPCR (Hamdan *et al.*, 2007). These results show that deletion of the β -arrestin clathrin box does not have a major negative affect on GPCR down-regulation and are fully consistent with a doubly mutated IV \rightarrow AA+LIEF \rightarrow AAEA β -arrestin 2 mutant clustering activated thyrotropin-releasing hormone receptors at AP-2-positive clathrin-coated structures and orchestrating endocytic uptake roughly equivalent to wild-type β -arrestin 2 at 10 min (Burtey *et al.*, 2007). We conclude that β -arrestin switching to a clathrin-dependent mode of association is not an obligate step during the formation of clathrin-coated vesicles and that the [DE]_nX₁₋₂FXX[FL]XXXR binding surface upon the platform subdomain of the β 2 appendage does represent a privileged interaction site, because it can be rapidly accessed by ARH or β -arrestin in the face of ongoing endocytic activity.

DISCUSSION

AP-2 ablation has a major inhibitory effect on the surface clustering and internalization of YXX ϕ -bearing proteins and also [DE]XXXL[LIM] (McCormick *et al.*, 2005)-bearing proteins. This confirms the chief sorting activity that this adaptor complex confers. Yet, at least in cultured cells, AP-2 silencing is still compatible with internalization of a subset of clathrin-dependent cargo; several groups have now shown this phenomenon independently (Hinrichsen *et al.*, 2003; Motley *et al.*, 2003; Barriere *et al.*, 2006; Keyel *et al.*, 2006; Maurer and Cooper, 2006; Eden *et al.*, 2007). The same is not true if clathrin levels are decreased by RNAi (Hinrichsen *et al.*, 2003; Motley *et al.*, 2003; Moskowitz *et al.*, 2005; Barriere *et al.*, 2006; Keyel *et al.*, 2006; Maurer and Cooper, 2006). Careful single cell analysis of clathrin knocked down populations reveals that rates of endocytosis become severely slowed when clathrin triskelia begin to be limiting (Moskowitz *et al.*, 2005). This difference indicates to us that although clathrin is essential for the fabrication of budding vesicles, AP-2 can be replaced to some extent by other clathrin-binding CLASPs such as Dab2, epsin, eps15, ARH, stonin 2, HIP1/Hip1R, and CALM. Correct surface deposition of Dab2 still permits clustering of LDL receptors when AP-2 is silenced; even though ARH depends upon AP-2 for proper placement in surface clathrin structures, ARH and Dab2 are functionally redundant and robust LDL uptake persists in either Dab2- or ARH-lacking HeLa cells (Keyel *et al.*, 2006; Maurer and Cooper, 2006; Eden *et al.*, 2007). The clathrin-, PtdIns(4,5)P₂- and cargo-binding qualities of Dab2 and other CLASPs likely accounts for the preservation of clathrin-coated vesicle formation in an AP-2 compromised background. Still, our ultrastructural analysis of cell membranes under these conditions shows that the clathrin lattices are not of normal dimensions, although invaginating buds are evident. The two AP-2 appendages operate as interaction hubs that can engage >20 CLASPs and accessory factors (Wang *et al.*, 1995; Traub, 2005; Edeling *et al.*, 2006b; Maldonado-Baez and Wendland, 2006; Schmid and McMahon, 2007), including type I phosphatidylinositol 4-phosphate 5-kinases (Bairstow *et al.*, 2006; Krauss *et al.*, 2006; Nakano-Kobayashi *et al.*, 2007) and the PtdIns(4,5)P₂ phos-




Figure 9. Clathrin-binding deficient β -arrestin 1 associates with AP-2. HeLa SS6 cells stably expressing β 2-YFP were transiently transfected with wild-type (WT) tdRFP- β -arrestin 1 (A), tdRFP- β -arrestin 1 with the IV \rightarrow AA activating mutation (B), or tdRFP- β -arrestin 1 (IV \rightarrow AA) + clathrin box mutation LIEL \rightarrow AAEA (C) or + clathrin box deletion Δ LIELD (D). Approximately 18 h after transfection, cells were imaged by TIR-FM to selectively observe the ventral surface. Representative images show tdRFP- β -arrestin 1 (left column), β 2-YFP (middle column), and merged (right column) signals. Note that despite a considerable cytosolic pool, there is near complete colocalization of β 2-YFP puncta with the tdRFP- β -arrestin 1 (IV \rightarrow AA) alone or with either clathrin box disruption. Bar, 10 μ m.

phatases synaptojanin 1 (Haffner *et al.*, 2000; Jha *et al.*, 2004) and OCRL (Ungewickell *et al.*, 2004). Given the vital role that PtdIns(4,5)P₂ plays in clathrin-coated vesicle assembly and budding at the plasma membrane, we suspect the residual

AP-2 we see in cells subject to siRNA knockdown probably contributes to LDL uptake. Our overall interpretation of the available data is that clathrin-coated structures never evolved to operate in the absence of AP-2, and is fully




Figure 10. Clathrin-binding deficient β -arrestin 1 dynamically associates with AP-2. HeLa SS6 cells stably expressing β 2-YFP were transiently transfected with tdRFP- β -arrestin 1 (IV \rightarrow AA) (A–C) or tdRFP- β -arrestin 1 (IV \rightarrow AA+ Δ LIELD) (D–F). Approximately 18 h after transfection, cells were imaged by TIR-FM at one frame every 5 s. (A) Representative frames from the tdRFP- β -arrestin 1 (IV \rightarrow AA)-expressing cells. β -arrestin 1 (left frame) and β 2-YFP (middle frame) show extensive colocalization (right frame). (B) A sequence of frames at 25-s intervals shows the simultaneous disappearance of tdRFP- β -arrestin 1 (IV \rightarrow AA) (middle row) and β 2-YFP (bottom row) from the evanescent field. The spot is the same as that boxed in A. (C) A line drawn along the axis of the box in A was used to create a kymograph. tdRFP- β -arrestin 1 IV \rightarrow AA (left column) and β 2-YFP (middle column) leave the evanescent field together (right column). (D) tdRFP- β -arrestin 1 (IV \rightarrow AA+ Δ LIELD)-expressing cells likewise show significant overlap with β 2-YFP as in depicted in A. (E) The boxed spot in D containing tdRFP- β -arrestin 1 (IV \rightarrow AA+ Δ LIELD) (middle row) and β 2-YFP (bottom row) disappears from the field (solid arrowhead) at 100 s as a second spot containing both proteins appears (open arrowhead). (F) A line drawn along the axis of the box in D was used to create a kymograph. tdRFP- β -arrestin 1 (IV \rightarrow AA+ Δ LIELD) (left column) and β 2-YFP (middle column) disappear together, whereas the appearance of arrestin in the second spot is slightly preceded by β 2-YFP. All horizontal bars, 10 μ m (A and D); vertical time bars, 60 s (C and F).

consistent with the lethal consequence of interfering with expression of certain AP-2 adaptor subunits in *C. elegans* (Grant and Hirsh, 1999; Shim and Lee, 2000; Kamikura and Cooper, 2003), *Drosophila* (Gonzalez-Gaitan and Jackle, 1997),

and mice (Mitsunari *et al.*, 2005). Harder to explain is the completely normal internalization rate of a CD8-LDL receptor chimera in HeLa cells containing <10% of the surface clathrin structures observed in AP-2 replete cells (Motley *et al.*, 2003).





Figure 11. Clathrin-binding deficient β -arrestin 1 associates with clathrin-coated structures in the absence of endogenous β -arrestins. Wild-type and β -arrestin 1/2 null mouse embryonic fibroblasts were lysed and resolved by SDS-PAGE (A; left) and transferred to nitrocellulose (A; right). Portions of the blots were probed with an anti- β -arrestin polyclonal antibody, anti-clathrin HC mAb TD.1, and anti- β 1/ β 2 subunit mAb 100/1, or with anti-tubulin mAb E7. The position of the molecular mass standards (in kilodaltons) is noted on the left. Alternatively, β -arrestin 1/2 null mouse embryonic fibroblasts were transiently transfected with tdRFP- β -arrestin 1 (red) wild type (B), the tdRFP- β -arrestin 1 (IV \rightarrow AA)-activating mutation (C), IV \rightarrow AA + clathrin box mutation LIEL \rightarrow AAEA (D), or IV \rightarrow AA + clathrin box deletion Δ LIELD (E). At 18 h after transfection, cells were incubated with 25 μ g/ml Tf488 (green) on 4°C on ice for 1 h to label transferrin receptor in clathrin-coated structures, and then they were rapidly imaged at 17°C by TIR-FM. Under these conditions, transferrin is found both at clathrin coated structures on the cell surface and already in peripheral endosomes. Magnified insets are denoted by white boxes; the IV \rightarrow AA and IV \rightarrow AA + clathrin box disruption β -arrestin mutants (middle inset) both colocalize with Tf488 (top inset), as denoted by arrowheads. Bar, 10 μ m.

Because of the high degree of sequence identity between the adaptor β 1 and β 2 subunits, gene silencing or targeted gene disruption of the β 2 subunit results in only a moderate endocytic phenotype. β 2 is probably the only subunit of AP-2 that can be replaced by an AP-1 counterpart, because the σ 1 subunit does not interact directly with the α subunit (Page and Robinson, 1995), and μ 2 subunit RNAi phenocopies the α subunit RNAi (Motley *et al.*, 2003; Huang *et al.*, 2004). We suspect that the opposite is also true, because it is known that β 2 subunits can incorporate into AP-1 *in vivo* (Page and Robinson, 1995; Sorkin *et al.*, 1995; Traub *et al.*, 1996). Also, at moderately high levels, ectopically expressed β 2-YFP can incorporate into AP-1 (Huang *et al.*, 2003; Keyel *et al.*, 2004), and the C-terminal region of ARH interacts similarly with AP-1 and AP-2 but not with AP-3 (He *et al.*, 2002; Mishra *et al.*, 2002b). All of the key specificity-determining residues at the platform and sandwich subdomain interaction interfaces are conserved between the β 1 and β 2

polypeptides. This must account for the functional activity of a hybrid AP-2 incorporating a β 1 chain. The apparent interchangeability of the β 1 and β 2 subunits, the localization of some eps15 at a juxtannuclear, TGN-like location (Tebar *et al.*, 1996; Kent *et al.*, 2002), and our detection of the β -arrestin 1 (IV \rightarrow AA) mutant at the juxtannuclear/TGN region (Figure 12) raises the question of whether known AP-2 β 2 binding partners also function normally together with AP-1. A very recent study in fact mapped an apparent AP-1-specific binding site on eps15 to the sequence ⁷²⁰ESFDGDFADFSTLS (Chi *et al.*, 2008). Remarkably, this region is identical to a peptide segment of eps15 cocrystallized at the sandwich site of the AP-2 β 2 appendage (Schmid *et al.*, 2006). The reason why deletion of this amino acid tract from eps15 perturbs only AP-1 binding (Chi *et al.*, 2008) is because the proximal tract of >10 DPF triplets facilitates AP-2 engagement through interaction with the platform subdomain of the α subunit appendage (Owen *et al.*, 1999; Brett *et al.*, 2002);

Figure 12. Down-regulation of the type 1 angiotensin II receptor by both tdRFP- β -arrestin 1 (IV \rightarrow AA) and β -arrestin (IV \rightarrow AA+ Δ LIELD). HEK293 cells stably expressing FLAG-tagged type I angiotensin II receptor were transiently transfected with tdRFP- β -arrestin 1 (IV \rightarrow AA) (A), or tdRFP- β -arrestin 1 (IV \rightarrow AA+ Δ LIELD) (B). Cells were starved for 1 h in starvation medium and then stimulated with 100 nM angiotensin II conjugated to Alexa488 (AngII; green) for 0, 5, or 20 min. Cells were washed, fixed, and examined by confocal microscopy. Representative images of medial focal planes are shown. Before stimulation, β -arrestin is largely diffuse in the cytosol but also present at the plasma membrane (arrows) or at a juxtannuclear location (asterisks). After 5 min of stimulation, β -arrestin clusters with angiotensin II at the plasma membrane (closed arrowheads), and on endosomes (open arrowheads). At 20 min after stimulation, nearly all β -arrestin and angiotensin II colocalize on larger endosomes. Bar, 10 μ m.



the appendage of the analogous subunit in AP-1, the γ subunit, lacks a platform subdomain, and binds eps15 only very weakly (Kent *et al.*, 2002; Nogi *et al.*, 2002). The fact that overexpression of an eps15 mutant lacking the above-mentioned 14-amino acid β -binding tract sharply slows exit of the MPR from the TGN (Chi *et al.*, 2008) argues that the β 1 and β 2 subunits do perform some similar functions at the TGN/endosome and plasma membrane, respectively.

Because eps15 contacts the β 2 appendage through the sandwich subdomain, a mutation that disrupts this interaction surface interferes with eps15 binding (Edeling *et al.*, 2006a; Schmid *et al.*, 2006). We find that this same mutation (Y815A) abolishes clathrin binding, indicating that eps15 and clathrin compete for a common site on the β 2 appendage sandwich subdomain (Edeling *et al.*, 2006a). Biochemical experiments show plainly that eps15 preloaded onto AP-2 is expelled upon clathrin assembly and eps15 fails to be incorporated along with AP-2 into assembled clathrin coats (Cuppers *et al.*, 1998). By contrast, ARH and the β -arrestins differ significantly from eps15 and several other CLASPs and accessory factors in that they both display only a single AP-2 binding determinant with an absolute selectivity for the platform subdomain of the β 2 appendage (Laporte *et al.*, 2000; He *et al.*, 2002; Mishra *et al.*, 2002b). Substantial data attest to the critical and selective importance of the β 2 appendage in the initial recruitment of GPCR- β -arrestin complexes to pre-existing sites of clathrin assembly. The clathrin box is located within a flexible, unstructured C-terminal loop (Milano *et al.*, 2002), even in the basal β -arrestin conformation. Yet β -arrestins are cytosolic in the absence of GPCR activation (Hamdan *et al.*, 2007), so, although the clathrin box is potentially accessible to the clathrin terminal domain, if the distal [DE]_nX₁₋₂FXX[FL]XXXR sequence is conformationally restrained, β -arrestins fail to associate appreciably with clathrin-coated structures. Similarly, when fused to GFP, the C-terminal region of β -arrestin 2 populates AP-2-positive clathrin structures at the cell surface but this colocalization is completely lost if the [DE]_nX₁₋₂FXX[FL]XXXR sequence is disrupted, even with an intact adjacent clathrin box (Schmid *et al.*, 2006). Also, the β -arrestin 1 IVF \rightarrow AAA triple mutant is not colocalized with AP-2 at steady state, despite the conformational relaxation affected by the IV to AA substitution (Burtey *et al.*, 2007). Mutagenic

inactivation of the AP-2 binding sequence in β -arrestin 2 still allows translocation of this CLASP to agonist-stimulated GPCRs on the cell surface, but clustering at AP-2-positive puncta is lost, again despite an intact clathrin box (Laporte *et al.*, 2000). Indeed, bioluminescence resonance energy transfer studies show that β -arrestin binding to liganded GPCRs temporally precedes an AP-2 β 2 appendage interaction (Hamdan *et al.*, 2007) and that mutation of the interaction surface on the β 2 platform subdomain prevents energy transfer to AP-2 (Hamdan *et al.*, 2007). By contrast, even with an inactivating mutation or complete deletion of the clathrin box, β -arrestin 1 still targets to clathrin-coated structures (Figures 9–12). Altogether, this argues strongly that the [DE]_nX₁₋₂FXX[FL]XXXR sequence is the principal determinant governing initial linkage of GPCRs with the endocytic machinery (Laporte *et al.*, 2000).

Our siRNA/reconstitution experiments reveal that ARH likewise uses the analogous interaction motif as the primary mode of clathrin-coat engagement. In fact, simultaneous gene silencing of AP-2 and Dab2 leads to stalling of the LDL receptor at the cell surface despite normal ARH levels and the clear presence of surface clathrin coats (Keyel *et al.*, 2006; Maurer and Cooper, 2006). The binding affinity of ARH (and β -arrestin) for the β 2 appendage is greater than its affinity for any other binding partner. ARH binds to the β 2 appendage, with a K_D value of \sim 1 μ M (Mishra *et al.*, 2005), compared with 22 μ M for a type I clathrin box LLDLD binding to clathrin (Miele *et al.*, 2004), 10–100 μ M for the Shc PTB domain binding to PtdIns(4,5)P₂ (Zhou *et al.*, 1995), and 2–5 μ M for various PTB domains binding to FXNPXY peptides (Li *et al.*, 1998; Howell *et al.*, 1999; Stolt *et al.*, 2003; Stolt *et al.*, 2005). In a sequential hub model for clathrin-coated vesicle assembly, it is proposed that AP-2-dependent interactions are diminished as clathrin buds progress toward late-stage events (Schmid *et al.*, 2006; Schmid and McMahon, 2007). In fact, it is conjectured that ARH and β -arrestins only remain associated with deeply invaginated buds by interacting directly with clathrin heavy chains (Schmid *et al.*, 2006). Given the 10-fold difference in binding affinity for the β 2 appendage and the clathrin terminal domain, which is also subject to direct competition by numerous other CLASPs and accessory proteins that have tandemly repeated clathrin boxes and are massed at the bud site (Robinson, 2004; Sorkin, 2004; Maldonado-Baez and Wendland, 2006), the biological ad-

vantage of moving to an apparently lower affinity association (at the clathrin hub) is not obvious.

The changing hub model was formulated, in part, to account for the inherent directionality of the clathrin-coat assembly process (Schmid *et al.*, 2006; Schmid and McMahon, 2007). Although our view is that CLASPs like ARH and β -arrestin, which associate physically with AP-2 through the β 2 appendage, do not necessarily switch to a clathrin-dependent interaction mode in a temporally-defined manner, our observations certainly do not generally invalidate the model, which invokes changing degrees of freedom as a function of ongoing lattice assembly events. Nor do our findings indicate that the clathrin box in either ARH or β -arrestin is functionally insignificant (Krupnick *et al.*, 1997; Laporte *et al.*, 2000; Kim and Benovic, 2002; Santini *et al.*, 2002; Garuti *et al.*, 2005). Rather, our data agree with several independent investigations showing the β -arrestin-AP-2 interaction typically initiates clustering of GPCRs into clathrin-coated structures and simply preclude ARH and β -arrestins from the set of potential endocytic factors subject to displacement by assembling clathrin triskelia. Intriguingly, because of the clear functional redundancy between the adaptor β 1 and β 2 subunits, and because only a single pool of cytosolic clathrin is used to construct all clathrin-coats within the cell, use of neither the $[DE]_nX_{1-2}FXX[FL]XXXX$ motif nor the clathrin box will ensure translocation of β -arrestin or ARH to only those AP-2 and clathrin-containing structures positioned at the cell surface. However, both the β -arrestins (Gaidarov *et al.*, 1999; Milano *et al.*, 2002) and ARH (Mishra *et al.*, 2002b) bind to PtdIns(4,5)P₂, a lipid concentrated in the inner leaflet of the plasma membrane. The phenomenon of coincidence detection, involving simultaneous contacts with transmembrane cargo receptors, lipids, AP-2, and then clathrin, likely provides the necessary selectivity. The striking translocation of the cytosolic pool of β -arrestin 1 upon angiotensin II application (Figure 12) is a graphic demonstration of this avidity-based phenomenon. Overall then, the β 2 appendage of AP-2 represents one hub within an intricate web of protein-protein interactions that promotes selective cargo endocytosis by facilitating initial CLASP recruitment.

ACKNOWLEDGMENTS

We thank Sasha Sorokin for generously sharing the β 2-YFP plasmid, Robert Lefkowitz for providing the arrestin-null mouse fibroblasts, Stéphane Laporte for the angiotensin II receptor-expressing HEK cells, and members of the Traub laboratory for critical reading of the manuscript. This work was funded by National Institutes of Health grants R01 DK53249 (to L.M.T.) and DE015180 (to E.T.E.), American Heart Association (AHA) Established Investigator Award 0540007N (to L.M.T.), and AHA predoctoral fellowship 0415428U (to P.A.K.).

REFERENCES

Aguilar, R. C., Ohno, H., Roche, K. W., and Bonifacino, J. S. (1997). Functional domain mapping of the clathrin-associated adaptor medium chains μ 1 and μ 2. *J. Biol. Chem.* *272*, 27160–27166.

Ahle, S., Mann, A., Eichelsbacher, U., and Ungewickell, U. (1988). Structural relationships between clathrin assembly proteins from the Golgi and the plasma membrane. *EMBO J.* *7*, 919–929.

Baird, S. F., Ling, K., Su, X., Firestone, A. J., Carbonara, C., and Anderson, R. A. (2006). Type 1y 661 phosphatidylinositol phosphate kinase directly interacts with AP2 and regulates endocytosis. *J. Biol. Chem.* *281*, 20632–20642.

Barriere, H., Nemes, C., Lechardeur, D., Khan-Mohammad, M., Fruh, K., and Lukacs, G. L. (2006). Molecular basis of Ub-dependent internalization of membrane proteins in mammalian cells. *Traffic* *7*, 282–297.

Blondeau, F. *et al.* (2004). Tandem MS analysis of brain clathrin-coated vesicles reveals their critical involvement in synaptic vesicle recycling. *Proc. Natl. Acad. Sci. USA* *101*, 3833–3838.

Brett, T. J., and Traub, L. M. (2006). Molecular structures of coat and coat-associated proteins: structure follows form. *Curr. Opin. Cell Biol.* *18*, 395–406.

Brett, T. J., Traub, L. M., and Fremont, D. H. (2002). Accessory protein recruitment motifs in clathrin-mediated endocytosis. *Structure* *10*, 797–809.

Brodsky, F. M. (1985). Clathrin structure characterized with monoclonal antibodies. II. Identification of in vivo forms of clathrin. *J. Cell Biol.* *101*, 2055–2062.

Burley, A., Schmid, E. M., Ford, M. G., Rappoport, J. Z., Scott, M. G., Marullo, S., Simon, S. M., McMahon, H. T., and Benmerah, A. (2007). The conserved isoleucine-valine-phenylalanine motif couples activation state and endocytic functions of β -arrestins. *Traffic* *8*, 914–931.

Camidge, D. R., and Pearse, B.M.F. (1994). Cloning of the *Drosophila* β -adaptin and its localization on expression in mammalian cells. *J. Cell Sci.* *107*, 709–718.

Chaudhuri, R., Lindwasser, O. W., Smith, W. J., Hurley, J. H., and Bonifacino, J. S. (2007). CD4 downregulation by HIV-1 Nef is dependent on clathrin and involves a direct interaction of Nef with the AP2 clathrin adaptor. *J. Virol.* *81*, 3877–3890.

Chi, S., Cao, H., Chen, J., and McNiven, M. (2008). Eps15 mediates vesicle trafficking from the trans-Golgi network via an interaction with clathrin adaptor AP-1. *Mol. Biol. Cell* *19*, 3564–3575.

Chin, D. J., Straubinger, R. M., Acton, S., Nathke, I., and Brodsky, F. M. (1989). 100-kDa polypeptides in peripheral clathrin-coated vesicles are required for receptor-mediated endocytosis. *Proc. Natl. Acad. Sci. USA* *86*, 9289–9293.

Coleman, S. H., Van Damme, N., Day, J. R., Noviello, C. M., Hitchin, D., Madrid, R., Benichou, S., and Guatelli, J. C. (2005). Leucine-specific, functional interactions between human immunodeficiency virus type 1 Nef and adaptor protein complexes. *J. Virol.* *79*, 2066–2078.

Collins, B. M., McCoy, A. J., Kent, H. M., Evans, P. R., and Owen, D. J. (2002). Molecular architecture and functional model of the endocytic AP2 complex. *Cell* *109*, 523–535.

Conner, S. D., and Schmid, S. L. (2003). Regulated portals of entry into the cell. *Nature* *422*, 37–44.

Cupers, P., Jadhav, A. P., and Kirchhausen, T. (1998). Assembly of clathrin coats disrupts the association between Eps15 and AP-2 adaptors. *J. Biol. Chem.* *273*, 1847–1850.

Dalal, S., Rosser, M. F., Cyr, D. M., and Hanson, P. I. (2004). Distinct roles for the AAA ATPases NSF and p97 in the secretory pathway. *Mol. Biol. Cell* *15*, 637–648.

Drake, M. T., Downs, M. A., and Traub, L. M. (2000). Epsin binds to clathrin by associating directly with the clathrin-terminal domain: evidence for cooperative binding through two discrete sites. *J. Biol. Chem.* *275*, 6479–6489.

Edeling, M. A., Mishra, S. K., Keyel, P. A., Steinhilber, A. L., Collins, B. M., Roth, R., Heuser, J. E., Owen, D. J., and Traub, L. M. (2006a). Molecular switches involving the AP-2 β 2 appendage regulate endocytic cargo selection and clathrin coat assembly. *Dev. Cell* *10*, 329–342.

Edeling, M. A., Smith, C., and Owen, D. (2006b). Life of a clathrin coat: insights from clathrin and AP structures. *Nat. Rev. Mol. Cell Biol.* *7*, 32–44.

Eden, E. R., Naoumova, R. P., Burden, J. J., McCarthy, M. I., and Soutar, A. K. (2001). Use of homozygosity mapping to identify a region on chromosome 1 bearing a defective gene that causes autosomal recessive homozygous hypercholesterolemia in two unrelated families. *Am. J. Hum. Genet.* *68*, 653–660.

Eden, E. R., Patel, D. D., Sun, X., Burden, J. J., Themis, M., Edwards, M., Lee, P., Neuwirth, C., Naoumova, R. P., and Soutar, A. K. (2002). Restoration of LDL-receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of *ARH1*. *J. Clin. Invest.* *110*, 1695–1702.

Eden, E. R., Sun, X. M., Patel, D. D., and Soutar, A. K. (2007). Adaptor protein Disabled-2 modulates low density lipoprotein (LDL) receptor synthesis in fibroblasts from patients with autosomal recessive hypercholesterolemia. *Hum. Mol. Genet.* *16*, 2751–2759.

Ehrlich, M., Boll, W., Van Oijen, A., Hariharan, R., Chandran, K., Nibert, M. L., and Kirchhausen, T. (2004). Endocytosis by random initiation and stabilization of clathrin-coated pits. *Cell* *118*, 591–605.

Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* *411*, 494–498.

Gaidarov, I., and Keen, J. H. (1999). Phosphoinositide-AP-2 interactions required for targeting to plasma membrane clathrin-coated pits. *J. Cell Biol.* *146*, 755–764.

Gaidarov, I., Krupnick, J. G., Falck, J. R., Benovic, J. L., and Keen, J. H. (1999). Arrestin function in G protein-coupled receptor endocytosis requires phosphoinositide binding. *EMBO J.* *18*, 871–881.

- Garcia, C. K. *et al.* (2001). Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. *Science* 292, 1394–1398.
- Garuti, R., Jones, C., Li, W. P., Michaely, P., Herz, J., Gerard, R. D., Cohen, J. C., and Hobbs, H. H. (2005). The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. *J. Biol. Chem.* 280, 40996–41004.
- Ghosh, P., Dahms, N. M., and Kornfeld, S. (2003). Mannose 6-phosphate receptors: new twists in the tale. *Nat. Rev. Mol. Cell Biol.* 4, 202–213.
- Girard, M., Allaire, P. D., McPherson, P. S., and Blondeau, F. (2005). Non-stoichiometric relationship between clathrin heavy and light chains revealed by quantitative comparative proteomics of clathrin-coated vesicles from brain and liver. *Mol. Cell. Proteomics* 4, 1145–1154.
- Gonzalez-Gaitan, M., and Jackle, H. (1997). Role of *Drosophila* α -adaptin in presynaptic vesicle recycling. *Cell* 88, 767–776.
- Grant, B., and Hirsh, D. (1999). Receptor-mediated endocytosis in the *Caenorhabditis elegans* oocyte. *Mol. Biol. Cell* 10, 4311–4326.
- Gurevich, V. V., and Gurevich, E. V. (2004). The molecular acrobatics of arrestin activation. *Trends Pharmacol. Sci.* 25, 105–111.
- Haffner, C., Paolo, G. D., Rosenthal, J. A., and de Camilli, P. (2000). Direct interaction of the 170 kDa isoform of synaptojanin 1 with clathrin and with the clathrin adaptor AP-2. *Curr. Biol.* 10, 471–474.
- Hamdan, F. F., Rochdi, M. D., Breton, B., Fessart, D., Michaud, D. E., Charest, P. G., Laporte, S. A., and Bouvier, M. (2007). Unraveling G protein-coupled receptor endocytosis pathways using real-time monitoring of agonist-promoted interaction between β -arrestins and AP-2. *J. Biol. Chem.* 282, 29089–29100.
- Hanson, S. M., Dawson, E. S., Francis, D. J., Van Eps, N., Klug, C. S., Hubbell, W. L., Meiler, J., and Gurevich, V. V. (2008a). A model for the solution structure of the rod arrestin tetramer. *Structure* 16, 924–934.
- Hanson, S. M., Vishnivetskiy, S. A., Hubbell, W. L., and Gurevich, V. V. (2008b). Opposing effects of inositol hexakisphosphate on rod arrestin and arrestin2 self-association. *Biochemistry* 47, 1070–1075.
- Harasaki, K., Lubben, N. B., Harbour, M., Taylor, M. J., and Robinson, M. S. (2005). Sorting of major cargo glycoproteins into clathrin-coated vesicles. *Traffic* 6, 1014–1026.
- Hawryluk, M. J., Keyel, P. A., Mishra, S. K., Watkins, S. C., Heuser, J. E., and Traub, L. M. (2006). Epsin 1 is a polyubiquitin-selective clathrin-associated sorting protein. *Traffic* 7, 262–281.
- He, G., Gupta, S., Yi, M., Michaely, P., Hobbs, H. H., and Cohen, J. C. (2002). ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin and AP-2. *J. Biol. Chem.* 277, 44044–44049.
- Heuser, J. (2000). The production of ‘cell cortices’ for light and electron microscopy. *Traffic* 1, 545–552.
- Hinrichsen, L., Harborth, J., Andrees, L., Weber, K., and Ungewickell, E. J. (2003). Effect of clathrin heavy chain- and α -adaptin specific small interfering RNAs on endocytic accessory proteins and receptor trafficking in HeLa cells. *J. Biol. Chem.* 278, 45160–45170.
- Höning, S., Ricotta, D., Krauss, M., Spate, K., Spolaore, B., Motley, A., Robinson, M., Robinson, C., Haucke, V., and Owen, D. J. (2005). Phosphatidylinositol-(4,5)-bisphosphate regulates sorting signal recognition by the clathrin-associated adaptor complex AP2. *Mol. Cell* 18, 519–531.
- Howell, B. W., Lanier, L. M., Frank, R., Gertler, F. B., and Cooper, J. A. (1999). The disabled 1 phosphotyrosine-binding domain binds to the internalization signals of transmembrane glycoproteins and to phospholipids. *Mol. Cell. Biol.* 19, 5179–5188.
- Huang, F., Jiang, X., and Sorkin, A. (2003). Tyrosine phosphorylation of the β 2 subunit of clathrin adaptor complex AP-2 reveals the role of a di-leucine motif in the epidermal growth factor receptor trafficking. *J. Biol. Chem.* 278, 43411–43417.
- Huang, F., Khvorova, A., Marshall, W., and Sorkin, A. (2004). Analysis of clathrin-mediated endocytosis of epidermal growth factor receptor by RNA interference. *J. Biol. Chem.* 279, 16657–16661.
- Janvier, K., and Bonifacino, J. S. (2005). Role of the endocytic machinery in the sorting of lysosome-associated membrane proteins. *Mol. Biol. Cell* 16, 4231–4242.
- Janvier, K., Kato, Y., Boehm, M., Rose, J. R., Martina, J. A., Kim, B. Y., Venkatesan, S., and Bonifacino, J. S. (2003). Recognition of dileucine-based sorting signals from HIV-1 Nef and LIMP-II by the AP-1 γ - σ 1 and AP-3 δ - σ 3 hemicomplexes. *J. Cell Biol.* 163, 1281–1290.
- Jha, A., Agostinelli, N. R., Mishra, S. K., Keyel, P. A., Hawryluk, M. J., and Traub, L. M. (2004). A novel AP-2 adaptor interaction motif initially identified in the long-splice isoform of synaptojanin 1, SJ170. *J. Biol. Chem.* 279, 2281–2290.
- Kaksonen, M., Toret, C. P., and Drubin, D. G. (2006). Harnessing actin dynamics for clathrin-mediated endocytosis. *Nat. Rev. Mol. Cell Biol.* 7, 404–414.
- Kalthoff, C., Alves, J., Urbanke, C., Knorr, R., and Ungewickell, E. J. (2002). Unusual structural organization of the endocytic proteins AP180 and epsin 1. *J. Biol. Chem.* 277, 8209–8216.
- Kamikura, D. M., and Cooper, J. A. (2003). Lipoprotein receptors and a disabled family cytoplasmic adaptor protein regulate EGL-17/FGF export in *C. elegans*. *Genes Dev.* 17, 2798–2811.
- Kent, H., McMahon, H., Evans, P., Benmerah, A., and Owen, D. (2002). γ -adaptin appendage domain. Structure and binding site for Eps15 and γ -synergin. *Structure* 10, 1139–1148.
- Keyel, P. A., Mishra, S. K., Roth, R., Heuser, J. E., Watkins, S. C., and Traub, L. M. (2006). A single common portal for clathrin-mediated endocytosis of distinct cargo governed by cargo-selective adaptors. *Mol. Biol. Cell* 17, 4300–4317.
- Keyel, P. A., Watkins, S. C., and Traub, L. M. (2004). Endocytic adaptor molecules reveal an endosomal population of clathrin by total internal reflection fluorescence microscopy. *J. Biol. Chem.* 279, 13190–13204.
- Kim, Y. M., and Benovic, J. L. (2002). Differential roles of arrestin-2 interaction with clathrin and adaptor protein 2 in G protein-coupled receptor trafficking. *J. Biol. Chem.* 277, 30760–30768.
- Knuehl, C., Chen, C. Y., Manalo, V., Hwang, P. K., Ota, N., and Brodsky, F. M. (2006). Novel binding sites on clathrin and adaptors regulate distinct aspects of coat assembly. *Traffic* 7, 1688–1700.
- Kohout, T. A., Lin, F. S., Perry, S. J., Conner, D. A., and Lefkowitz, R. J. (2001). β -arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. *Proc. Natl. Acad. Sci. USA* 98, 1601–1606.
- Krauss, M., Kukhtina, V., Pechstein, A., and Haucke, V. (2006). Stimulation of phosphatidylinositol kinase type I-mediated phosphatidylinositol (4,5)-bisphosphate synthesis by AP-2 μ -cargo complexes. *Proc. Natl. Acad. Sci. USA* 103, 11934–11939.
- Krupnick, J. G., Santini, F., Gagnon, A. W., Keen, J. H., and Benovic, J. L. (1997). Modulation of the arrestin-clathrin interaction in cells. Characterization of beta-arrestin dominant-negative mutants. *J. Biol. Chem.* 272, 32507–32512.
- Laporte, S. A., Miller, W. E., Kim, K. M., and Caron, M. G. (2002). β -arrestin/AP-2 interaction in G protein-coupled receptor internalization. Identification of a β -arrestin binding site in β 2-adaptin. *J. Biol. Chem.* 277, 9247–9254.
- Laporte, S. A., Oakley, R. H., Holt, J. A., Barak, L. S., and Caron, M. G. (2000). The interaction of β -arrestin with the AP-2 adaptor is required for the clustering of β 2-adrenergic receptor into clathrin-coated pits. *J. Biol. Chem.* 275, 23120–23126.
- Li, S. C., Zwahlen, C., Vincent, S. J., McGlade, C. J., Kay, L. E., Pawson, T., and Forman-Kay, J. D. (1998). Structure of a Numb PTB domain-peptide complex suggests a basis for diverse binding specificity. *Nat. Struct. Biol.* 5, 1075–1083.
- Lundmark, R., and Carlsson, S. R. (2002). The β -appendages of the four adaptor-protein (AP) complexes: structure and binding properties, and identification of sorting nexin 9 as an accessory protein to AP-2. *Biochem. J.* 362, 597–607.
- Maldonado-Baez, L., and Wendland, B. (2006). Endocytic adaptors: recruiters, coordinators and regulators. *Trends Cell Biol.* 16, 505–513.
- Maurer, M. E., and Cooper, J. A. (2006). The adaptor protein Dab2 sorts LDL receptors into coated pits independently of AP-2 and ARH. *J. Cell Sci.* 119, 4235–4246.
- McCormick, P. J., Martina, J. A., and Bonifacino, J. S. (2005). Involvement of clathrin and AP-2 in the trafficking of MHC class II molecules to antigen-processing compartments. *Proc. Natl. Acad. Sci. USA* 102, 7910–7915.
- McPherson, P. S., and Ritter, B. (2005). Peptide motifs: building the clathrin machinery. *Mol. Neurobiol.* 32, 73–87.
- Miele, A. E., Watson, P. J., Evans, P. R., Traub, L. M., and Owen, D. J. (2004). Two distinct interaction motifs in amphiphysin bind two independent sites on the clathrin terminal domain β -propeller. *Nat. Struct. Mol. Biol.* 11, 242–248.
- Milano, S. K., Kim, Y. M., Stefano, F. P., Benovic, J. L., and Brenner, C. (2006). Nonvisual arrestin oligomerization and cellular localization are regulated by inositol hexakisphosphate binding. *J. Biol. Chem.* 281, 9812–9823.
- Milano, S. K., Pace, H. C., Kim, Y. M., Brenner, C., and Benovic, J. L. (2002). Scaffolding functions of arrestin-2 revealed by crystal structure and mutagenesis. *Biochemistry* 41, 3321–3328.

- Mishra, S. K., Hawryluk, M. J., Brett, T. J., Keyel, P. A., Dupin, A. L., Jha, A., Heuser, J. E., Fremont, D. H., and Traub, L. M. (2004). Dual-engagement regulation of protein interactions with the AP-2 adaptor α appendage. *J. Biol. Chem.* *279*, 46191–46203.
- Mishra, S. K., Keyel, P. A., Edeling, M. A., Owen, D. J., and Traub, L. M. (2005). Functional dissection of an AP-2 β 2 appendage-binding sequence within the autosomal recessive hypercholesterolemia (ARH) protein. *J. Biol. Chem.* *280*, 19270–19280.
- Mishra, S. K., Keyel, P. A., Hawryluk, M. J., Agostinelli, N. R., Watkins, S. C., and Traub, L. M. (2002a). Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor. *EMBO J.* *21*, 4915–4926.
- Mishra, S. K., Watkins, S. C., and Traub, L. M. (2002b). The autosomal recessive hypercholesterolemia (ARH) protein interfaces directly with the clathrin-coat machinery. *Proc. Natl. Acad. Sci. USA* *99*, 16099–16104.
- Mitsunari, T., Nakatsu, F., Shioda, N., Love, P. E., Grinberg, A., Bonifacino, J. S., and Ohno, H. (2005). Clathrin adaptor AP-2 is essential for early embryonal development. *Mol. Cell. Biol.* *25*, 9318–9323.
- Morris, S. M., and Cooper, J. A. (2001). Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2. *Traffic* *2*, 111–123.
- Moskowitz, H. S., Yokoyama, C. T., and Ryan, T. A. (2005). Highly cooperative control of endocytosis by clathrin. *Mol. Biol. Cell* *16*, 1769–1776.
- Motley, A., Bright, N. A., Seaman, M. N., and Robinson, M. S. (2003). Clathrin-mediated endocytosis in AP-2-depleted cells. *J. Cell Biol.* *162*, 909–918.
- Musacchio, A., Smith, C. J., Roseman, A. M., Harrison, S. C., Kirchhausen, T., and Pearse, B. M. (1999). Functional organization of clathrin in coats: combining electron cryomicroscopy and X-ray crystallography. *Mol. Cell* *3*, 761–770.
- Nakano-Kobayashi, A., Yamazaki, M., Unoki, T., Hongu, T., Murata, C., Taguchi, R., Katada, T., Frohman, M. A., Yokozeki, T., and Kanaho, Y. (2007). Role of activation of PIP5K γ 661 by AP-2 complex in synaptic vesicle endocytosis. *EMBO J.* *26*, 1105–1116.
- Nathke, I. S., Heuser, J., Lupas, A., Stock, J., Turck, C. W., and Brodsky, F. M. (1992). Folding and trimerization of clathrin subunits at the triskelion hub. *Cell* *68*, 899–910.
- Nogi, T. *et al.* (2002). Structural basis for the accessory protein recruitment by the γ -adaptin ear domain. *Nat. Struct. Biol.* *9*, 527–531.
- Ohno, H., Stewart, J., Fournier, M.-C., Bosshart, H., Rhee, I., Miyatake, S., Saito, T., Galluser, A., Kirchhausen, T., and Bonifacino, J. S. (1995). Interaction of tyrosine-based sorting signals with clathrin-associated proteins. *Science* *269*, 1872–1875.
- Owen, D. J., Vallis, Y., Noble, M. E., Hunter, J. B., Dafforn, T. R., Evans, P. R., and McMahon, H. T. (1999). A structural explanation for the binding of multiple ligands by the α -adaptin appendage domain. *Cell* *97*, 805–815.
- Owen, D. J., Vallis, Y., Pearse, B. M., McMahon, H. T., and Evans, P. R. (2000). The structure and function of the β 2-adaptin appendage domain. *EMBO J.* *19*, 4216–4227.
- Page, L., and Robinson, M. (1995). Targeting signals and subunit interactions in coated vesicle adaptor complexes. *J. Cell Biol.* *131*, 619–630.
- Praefcke, G. J., Ford, M. G., Schmid, E. M., Olesen, L. E., Gallop, J. L., Peak-Chew, S. Y., Vallis, Y., Babu, M. M., Mills, I. G., and McMahon, H. T. (2004). Evolving nature of the AP2 α -appendage hub during clathrin-coated vesicle endocytosis. *EMBO J.* *23*, 4371–4383.
- Rappoport, J. Z., and Simon, S. M. (2008). A functional GFP-fusion for imaging clathrin-mediated endocytosis. *Traffic* (*in press*).
- Ritter, B., Denisov, A. Y., Philie, J., Deprez, C., Tung, E. C., Gehring, K., and McPherson, P. S. (2004). Two WXXF-based motifs in NECAPs define the specificity of accessory protein binding to AP-1 and AP-2. *EMBO J.* *23*, 3701–3710.
- Robinson, M. S. (2004). Adaptable adaptors for coated vesicles. *Trends Cell Biol.* *14*, 167–174.
- Rohrer, J., Schweizer, A., Russell, D., and Kornfeld, S. (1996). The targeting of lamp1 to lysosomes is dependent on the spacing of its cytoplasmic tail tyrosine sorting motif relative to the membrane. *J. Cell Biol.* *132*, 565–576.
- Santini, F., Gaidarov, I., and Keen, J. H. (2002). G protein-coupled receptor/arrestin3 modulation of the endocytic machinery. *J. Cell Biol.* *156*, 665–676.
- Schmid, E. M., Ford, M. G., Burtey, A., Praefcke, G. J., Peak Chew, S. Y., Mills, I. G., Benmerah, A., and McMahon, H. T. (2006). Role of the AP2 β -appendage hub in recruiting partners for clathrin coated vesicle assembly. *PLoS Biol.* *4*, e262.
- Schmid, E. M., and McMahon, H. T. (2007). Integrating molecular and network biology to decode endocytosis. *Nature* *448*, 883–888.
- Scott, M. G., Benmerah, A., Muntaner, O., and Marullo, S. (2002). Recruitment of activated G protein-coupled receptors to pre-existing clathrin-coated pits in living cells. *J. Biol. Chem.* *277*, 3552–3559.
- Shaner, N. C., Campbell, R. E., Steinbach, P. A., Giepmans, B. N., Palmer, A. E., and Tsien, R. Y. (2004). Improved monomeric red, orange and yellow fluorescent proteins derived from *Discosoma* sp. red fluorescent protein. *Nat. Biotechnol.* *22*, 1567–1572.
- Shim, J., and Lee, J. (2000). Molecular genetic analysis of *apm-2* and *aps-2*, genes encoding the medium and small chains of the AP-2 clathrin-associated protein complex in the nematode *Caenorhabditis elegans*. *Mol. Cells* *10*, 309–316.
- Sorkin, A. (2004). Cargo recognition during clathrin-mediated endocytosis: a team effort. *Curr. Opin. Cell Biol.* *16*, 392–399.
- Sorkin, A., McKinsey, T., Shih, W., Kirchhausen, T., and Carpenter, G. (1995). Stoichiometric interaction of the epidermal growth factor receptor with the clathrin-associated protein complex AP-2. *J. Biol. Chem.* *270*, 619–625.
- Sorkina, T., Huang, F., Beguinot, L., and Sorkin, A. (2002). Effect of tyrosine kinase inhibitors on clathrin-coated pit recruitment and internalization of epidermal growth factor receptor. *J. Biol. Chem.* *277*, 27433–27441.
- Stolt, P. C., Chen, Y., Liu, P., Bock, H. H., Blacklow, S. C., and Herz, J. (2005). Phosphoinositide binding by the disabled-1 PTB domain is necessary for membrane localization and reelin signal transduction. *J. Biol. Chem.* *280*, 9671–9677.
- Stolt, P. C., Jeon, H., Song, H. K., Herz, J., Eck, M. J., and Blacklow, S. C. (2003). Origins of peptide selectivity and phosphoinositide binding revealed by structures of Disabled-1 PTB domain complexes. *Structure* *11*, 569–579.
- Storez, H. *et al.* (2005). Homo- and hetero-oligomerization of β -arrestins in living cells. *J. Biol. Chem.* *280*, 40210–40215.
- Tebar, F., Sorkina, T., Sorkin, A., Ericsson, M., and Kirchhausen, T. (1996). eps15 is a component of clathrin-coated pits and vesicles and is located at the rim of clathrin-coated pits. *J. Biol. Chem.* *271*, 28727–28730.
- Traub, L. M. (2005). Common principles in clathrin-mediated sorting at the Golgi and the plasma membrane. *Biochim. Biophys. Acta* *1744*, 415–437.
- Traub, L. M., Bannykh, S. I., Rodel, J. E., Aridor, M., Balch, W. E., and Kornfeld, S. (1996). AP-2-containing clathrin coats assemble on mature lysosomes. *J. Cell Biol.* *135*, 1801–1804.
- Traub, L. M., Downs, M. A., Westrich, J. L., and Fremont, D. H. (1999). Crystal structure of the α appendage of AP-2 reveals a recruitment platform for clathrin-coat assembly. *Proc. Natl. Acad. Sci. USA* *96*, 8907–8912.
- Traub, L. M., Kornfeld, S., and Ungewickell, E. (1995). Different domains of the AP-1 adaptor complex are required for Golgi membrane binding and clathrin recruitment. *J. Biol. Chem.* *270*, 4933–4942.
- Ungewickell, A., Ward, M. E., Ungewickell, E., and Majerus, P. W. (2004). The inositol polyphosphate 5-phosphatase Ocr1 associates with endosomes that are partially coated with clathrin. *Proc. Natl. Acad. Sci. USA* *101*, 13501–13506.
- Ungewickell, E. J., and Hinrichsen, L. (2007). Endocytosis: clathrin-mediated membrane budding. *Curr. Opin. Cell Biol.* *19*, 417–425.
- Walther, K., Diril, M. K., Jung, N., and Haucke, V. (2004). Functional dissection of the interactions of stonin 2 with the adaptor complex AP-2 and synaptotagmin. *Proc. Natl. Acad. Sci. USA* *101*, 964–969.
- Wang, L. H., Sudhof, T. C., and Anderson, R. G. (1995). The appendage domain of α -adaptin is a high affinity binding site for dynamin. *J. Biol. Chem.* *270*, 10079–10083.
- White, S., Miller, K., Hopkins, C., and Trowbridge, I. S. (1992). Monoclonal antibodies against defined epitopes of the human transferrin receptor cytoplasmic tail. *Biochim. Biophys. Acta* *1136*, 28–34.
- Zhou, M. M., Ravichandran, K. S., Olejniczak, E. F., Petros, A. M., Meadows, R. P., Sattler, M., Harlan, J. E., Wade, W. S., Burakoff, S. J., and Fesik, S. W. (1995). Structure and ligand recognition of the phosphotyrosine binding domain of Shc. *Nature* *378*, 584–592.
- Zhu, Y., Traub, L. M., and Kornfeld, S. (1999). High-affinity binding of the AP-1 adaptor complex to trans-Golgi network membranes devoid of mannose 6-phosphate receptors. *Mol. Biol. Cell* *10*, 537–549.